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1 INTRODUCTION 
1.1 Protein therapeutics 
Two major breakthroughs in the history of biochemistry are particularly notable, 
i) the elucidation of nucleic acids as carrying information molecular, which have 
been drawn significant attention by scientist of the time in the area of bio-related 
domain1 2; ii) the presentation of proteins as many biogenic activities. Proteins, 
commonly range in length from 100 to 1000 amino acids, are synthesized on 
ribosomes as linear chains of amino acids forming polypeptides in a specific order 
dictated from information encoded in the cellular DNA and then fold into tertiary 
structure to achieve their full function. Proteins are responsible for nearly every 
task of cellular life, including shaping cells, transporting essential nutrients, 
catalyzing biochemical reactions, and inner organization, product manufacture 
and waste cleanup, and routine maintenance, representing biomolecules with most 
functional and diverse character within living organisms3 4 5 6 7. By the most 
conservative calculation, human body synthesizes at least 30,000 different kinds 
of proteins to maintain the daily function of body and proteins hold 20% of a cell 
weight8 9 10 11. Viewed from the perspective of pathogenesis, these estimates are 
provided with enormous challenge to human being healthy, as diseases may arise 
from when any of these proteins perform misfolding, aggregation, or other kinds 
of abnormalities, or present in a relative high or low active concentration4 12 11 13 
14.  
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Protein therapeutics in general have gained dramatically attention and widely used 
in almost every field of medicine since the milestone protein therapeutics, clinical 
recombinant human insulin, was approved by the US Food and Drug 
Administration (FDA) in 19824. Since then, more than 130 proteins or peptides 
have been approved by FDA for clinical applications, such as cancer therapy, 
diabetes mellitus, hemophilia, and AIDS, and many more are in development4 15 
16 . Compared to small molecular and nucleic acid drug, due to the amino-acid- 
based secondary and tertiary structure, protein therapy represents an innovative 
approach with higher specificity than many simple small molecular drugs and 
lower risk for potential genetic adverse effects in contrast to gene therapy. In 
addition to pharmaceuticals, direct protein delivery into the intracellular space 
provides a wide range of biological applications including specific interaction 
with metabolic processes or signaling pathways. Based on pharmacological 
activity of active protein, the function of active protein can be basically divided 
into five groups: (a) Replacing a particular activity in case of protein deficient or 
abnormal; such as insulin-based drugs for treatment of diabetes17 18 19 20; Factor 
VIII in Haemophilia A and Factor III Haemophilia A could replace the deficient 
clotting factor21 22 23, and so on. (b) Augmenting an existing pathway; the most 
significant example is that the recombinant erythropoietin used to increase 
erythrocyte production when patients suffer from anaemia or myelodysplastic 
syndrome caused by chemotherapy24 25 26. (c) Providing a novel function or 
activity; in this case, the endogenous proteins extracted from other organisms are 
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used to function as novel activity in the human body. For example, L-
Asparaginase, purified from E.coli, can be applied to reduce the concentration of 
asparagine in serum, which is needed for acute lymphoblastic leukaemia, thus 
inhibiting proliferation of cancer cells27 28. (d) Interfering with a molecule or 
organism; many protein therapeutics in this group use the antigen recognition sites 
of immunoglobulin (Ig) molecules or the receptor binding-domains of native 
protein ligands to guide the immune system to destroy the aimed targeted 
molecules or cells. Such as, the immunoadhesin etanercept, a fusion between two 
human proteins: tumor necrosis factor TNF) receptor and the Fc region of the 
human antibody protein IgG1 was used to treat inflammatory arthritis and 
psoriasis29 30 31. The most attractive one is PD-1, a cell surface receptor expressed 
on T cells and pro-B cells, which could down regulate the immune system by 
preventing the activation of T cells. When PD-1 inhibitors (approved by FDA) are 
used to block the PD-1, which then active the immune system to attack tumors 
and are successfully treated with some types of cancer cell32 33 34. (e) Working as 
the vaccines or drugs. Though there are currently no clinical approved 
therapeutics in this area, many scientists are turning their effort in this new 
promising discipline. For example, transgenic tobacco plants (Nicotiana 
benthamiana) are used for diagnosis and therapy to some special kinds of disease35 
36 37 38. Protein therapeutics show their promising prospect and are still in their 
fancy, many kinds of protein therapeutics will become realization along with the 
thorough research from biochemistry scientists. 
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Therapeutic protein approaches are well established for the extracellular 
replacement of deficient proteins, immune-modulating cytokines and vaccines, 
the application of therapeutic antibodies, or antibody-drug conjugates 4. Effective 
delivery of functional proteins to intracellular target sites would enormously 
expand the repertoire of therapeutic protein applications; thus creating a strong 
demand of robust intracellular transfer technologies39 40 41. A major bottleneck to 
expand protein therapy is to obtain efficient delivery to the target sites without 
affecting their natural function. Hence, many strategies have been followed to 
enable controlled intracellular delivery of therapeutic proteins, such as polymeric 
nanoparticles42 43, hydrogels and nanocapsules44 45, liposomes46 47, cell penetrating 
peptides (CPP)48 49 and protein–transduction domains (PTD)50 51 52. One particular 
challenge is the versatile production of stable protein complexes with full 
bioactivity. Irreversible covalent modifications may affect protein activity, and 
non-covalent ionic or hydrophobic interactions with carriers do not always 
provide sufficient stability due to the diverse nature of different cargo proteins. 
An elegant solution to this problem has been developed by Kataoka and 
colleagues53 54. Lysine amino groups were covalently modified with citraconic 
anhydride, resulting in charge-converted negatively charged proteins suitable for 
polyion complex micelle formation with cationic polymers. Upon cellular uptake 
of the protein micelles, the pH-sensitive citraconic amide bonds are reversed 
within the acidic endosomal compartments, recovering the free bioactive form of 
the proteins. 
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1.2 Barriers and strategies for transduction protein to the desired 
destination 
Protein therapy represents an innovative approach with higher specificity and 
complex set of functions and superior biocompatibility than many simple small 
molecular drugs, protein therapeutics also exhibit lower risk for potential genetic 
of permanent adverse effects comparing to gene therapy4. Although past few 
decades have witnessed considerable progress of protein-based therapeutics, a 
major bottleneck to expand protein therapy is their efficient delivery to the target 
sites without affecting their natural functions. Oral route would be preferred to 
any other administration form of a drug because of its high levels of patient 
acceptance and long term compliance55 56 57 58, but for now it is a huge challenge 
to protect the therapeutics protein from degrading by high proteolytic activity and 
harsh conditions in the gastro intestinal tract because of its unfavorable low pH 
physiochemical environment and abundant of enzyme59 60. Till recent, injections 
(i.e. intravenous, intramuscular or subcutaneous route) of therapeutics are the 
most common route for administrating the protein drugs or peptides in vivo60-61, 
it is an passive diffusion process for intramuscular and subcutaneous route which 
restrict their use for inner organs. To date, most therapeutics proteins are taken by 
the intravenous injection, when the protein therapeutics applied in this route, 
proteins suffer from poor stability in the serum because of most proteins are 
negative charged at neutral pH, unfolding and aggregation resulting in 
transformational three-dimensional structure62. Protein also surround by a 
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complicated environment with proteolytic and chemical degradation, or 
eliminating by the immune system of the organism63. It is also very necessary to 
prolong the in vivo half-life of therapeutics protein in order to enhance the activity 
time of proteins to the focal of the target.  
Besides these, after a long journey, intracellular proteins therapeutics arriving at 
the target destination then should overcome the natural barrier of bilayer 
phospholipid structure to enter into the cells.  Uptakes usually proceed through 
the endocytosis mechanism into endosomes and subsequently lysosomes, which 
present an acidic and enzyme-rich environment64 65 66. It is a very tricky problem 
to avoid degrading by enzymes and maintain protein bioactivity release to the 
cytoplasm. Hence, the mentioned obstacles represent a reality to restrict the 
widespread applications of proteins as therapeutic strategies, but also maintain a 
tremendous opportunity for the drug delivery domain4. Many strategies have been 
followed to enable extension of circulation time and masking immunogenicity of 
protein drugs by conjugation of the protein with macromolecules like 
poly(ethylene glycol) (PEG) and injectable controlled delivery of therapeutic 
proteins, such as thermal67 68, light redox69 70, and magnetic stimuli-triggered 
functional units combined with a number of synthetic materials, including 
liposomes71 72, and polymers73. Dai and colleagues have developed single-walled 
carbon nanotubes (SWNTs) as the bovine serum albumin (BSA) and streptavidin 
(SA) vector, and presented evidence that the uptake mechanism of protein-SWNT 
is through clathrin-dependent endocytosis as the pathway74 75. Other kinds of 
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inorganic nanomaterials were also studied as the protein carrier, such as gold 
nanomaterial76 77, mesoporous silica nanoparticles78 79 and upconversion 
nanoparticles80. The main drawback of these nanomaterial protein systems comes 
from the difficult metabolism of the inorganic carriers, and the inorganic 
nanomaterials staying in vivo for long time could possible result in other kinds of 
aside effects to the organism. Many more biocompatibility delivery systems have 
been developed. Intracellular transduction of proteins can also be achieved by 
attachment of cell-penetrating peptides (CPPs)49 81 82 and protein-transduction 
domains (PTDs)50 83 or genetic engineering of supercharged proteins84 85 or by 
anchored targeting units86. 
1.3 Aim of this thesis 
Protein therapeutics represent burgeoning biopharmaceuticals in clinical 
applications, and many strategies have been developed for delivery of protein into 
focus. The efficiency transduction of proteins without denaturing its activity into 
the targeting sites is still an important ongoing task. Herein, based on some work 
in our group, current thesis is to focus on the intracellular delivery of protein 
without loss of function.  
The first aim of this thesis was the development of a high efficiency protein 
transduction system by synthetic sequence defined polymers. CPPs as carriers are 
widely used strategies for protein delivery, but major limitations of their 
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application are low efficiency of intracellular delivery and possible reduction of 
protein activity during derivatization49, 81-82. So an alternative option, via cationic 
polymers, has been developed to enhance the efficiency of protein delivery. Much 
effort has been put to form a formulation by electrostatic absorption between 
polymer and charged protein, which is not stable exposed in the organisms or 
blood, so a high efficiency carrier that could transduce protein into cells and put 
to good use of its biological activity is needed to be exploited. pH-sensitive 
covalent modification of proteins with a structure defined histidine-rich cationic 
oligomer (689)87 for efficient intracellular transduction and traceless release of 
functional proteins was to be developed. Enhanced Green fluorescent protein 
(EGFP)88, as model for the visualization of protein transduction, and RNase A89, 
as therapeutic protein with antitumoral effect, were to be modified with the pH-
sensitive bifunctional azidomethyl-methylmaleic anhydride AzMMMan linker90 
91. And sequence defined oligomer 689 was to be coupled with DBCO and used 
to modify EGFP-AzMMMan and RNase A-AzMMMan by copper free click 
chemistry. The impact of modification degree was to evaluate on the 
internalization and cellular distribution of EGFP as well as the biological effect 
of RNase A conjugates at various ratios.   
The second aim of this thesis was to evaluate intracellular delivery of protein 
conjugates by covalent combination with targeting ligand and an endosomal 
escape lytic peptide. Natural evolution has already presented very potent 
polycation-free protein delivery in the form of bacterial cytotoxins92 93 94 95. These 
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protein toxins internalize by endocytosis, followed by subsequent translocation of 
a toxin subunit across the endosomal membrane. For example, Diphtheria toxin 
consists of a toxic protein unit A, which is disulfide-linked with a delivery protein 
unit B. The delivery unit B contains two subdomains, which are required to 
facilitate the distinct delivery steps of cellular uptake and endosomal escape 
separately. One subunit mediates cell surface receptor binding (to heparin-binding 
epidermal growth factor precursor) triggering receptor-mediated endocytosis. The 
other represents a translocation domain, which at endosomal low pH undergoes a 
conformational change and inserts into the endosomal membrane, facilitating 
release of the toxic subunit A (inhibitor of cellular protein translation) into the 
cytosol after disulfide bond cleavage from unit B96 97. The potency of cytotoxins 
has already been translated into the generation of therapeutic immunotoxins, 
where researchers replaced the receptor-binding subunit with a target-specific 
antibody fragment or receptor ligands98 99 100 101 102 103 104.  
Folate receptor (FR) proteins are selectively overexpressed on the surface of brain, 
kidney, lung, and breast cancer cells compared to normal cells, folate ligand 
exhibits high affinity to the FR highly expressed on these tumors cells. Imitating 
the immunotoxin strategy in an artificial context, polycation-free multifunctional 
conjugates were to be developed, RNase A89 as cargo protein, polyethylene 
glycol-folate (PEG-folate) for folic acid receptor (FR) mediated cellular uptake105 
106 107 108, and INF7, an influenza hemagglutinin derived synthetic endosomal pH-
responsive peptide for endosomal escape109 110. These functional units were to be 
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attached to RNase A by the aforementioned AzMMMan/DBCO traceless-linker 
system. The biological activity of RNase A was to be tested when modified with 
both PEG-folate and INF7 units, or modified with PEG-folate and INF7 units 
alone.  Meanwhile, EGFP as a probe protein was to be modified as the mentioned 
strategy, and the cytoplasmic intracellular of EGFP should be visualized when 
modified with both functional units.  
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2 MATERIALS 
2.1 Chemicals 
Dimethylmaleic anhydride, N-bromosuccinimide, benzoyl peroxide, sodium 
azide, Sodium bicarbonate, FITC, and RNase A (from bovine pancreas), RNA 
(Mr 5000-8000, Torula utilis) were purchased from Sigma-Aldrich (Munich, 
Germany). 2,4,6-Trinitrobenzenesulfonic (TNBS) acid solution 1M in water was 
purchased from Fluka (Germany). Dibenzylcyclooctyne-PEG4-maleimide 
(DBCO-PEG4-maleimide) and DBCO-NHS ester were purchased from Jena 
Bioscience (Jena, Germany). INF7 peptide (GLFE AIEG FIEN GWEG MIDG 
WYGC-amide) was purchased from Biosyntan (Berlin, German). Cyanine5 dye 
NHS ester (Cy5-NHS) was obtained from Lumiprobe (Hannover, Germany). 
Sephadex G-25 and Sephadex G-10 material were supplied by GE Healthcare 
(Freiburg, Germany).  Isopropyl-β-D-thiogalactopyran oside (IPTG) was 
purchased from Biomol (Hamburg, Germany). 
2.2 Materials for solid-phase synthesis 
2-Chlorotrityl chloride resin, Fmoc-PEG28-OH, tBu-Glu(OH)-Fmoc, N-
(trifluoroacetyl) pteroic acid, peptide grade dimethylformamide (DMF), N,N-
diisopropylethylamine (DIPEA), piperidine, and trifluoroacetic acid (TFA), 1-
hydroxy-benzotriazole (HOBt), triisopropylsilane (TIS), tris(2-carboxyethyl) 
phosphine (TCEP), 1,8-diazabicyc [5.4.0] undec-7-ene (DBU), 3,6-dioxa-1,8-
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octanedithiol (DODT), were purchased from Iris Biotech (Marktredwitz, 
Germany). Benzotriazol-1-yl-oxy-tris-pyrrolidino-phosphonium 
hexafluorophosphate (Pybop) and syringe microreactors were obtained from 
Multisyntech GmbH (Witten, Germany).  
2.3 Solvents 
Dichloromethane (DCM), Methanol (MeOH), Tetrahydrofuran (THF) were 
purchased from Merck (Darmstadt, Germany). Chloroform (CHCl3), n-hexane, n-
heptane, Dimethyl sulfoxide (DMSO), Acetonitrile (ACN), Diethyl ether (Et2O) 
were obtained from Sigma Aldrich (Munich, Germany). All solvents were 
purified by distillation and dried before use. Water was used after purification and 
deionization. Deuterated solvents were bought from Sigma Aldrich. 
2.4 Cell culture material 
Cell culture media, antibiotics, and fetal bovine serum (FBS) were purchased from 
Invitrogen (Karlsruhe, Germany). Anticoagulated human red blood cells 
(obtained from LMU Clinics-Campus Großhadern, Munich, Germany). All cell 
culture consumables (flasks, dishes, well plates) were purchased from NUNC 
(Langenselbold, Germany) or TPP (Trasadingen, Switzerland). 
2.4 Bacteria strains 
E.coli protein expression strain BL21(DE3)plysS was purchased from Novagen 
(Merck4biosciences, Darmstadt, Germany). 
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2.5 Buffers 
Disodium hydrogen phosphate - citric acid buffer (pH 4.0, pH 5.0, pH 6.0), PBS 
buffer (pH 7.4, pH 8.0), Hepps buffer (pH 7.3, pH 8.0, pH 8.5, pH 9.0). TNBS 
buffer.  
2.6 Cell lines 
Name Description ATCC number 
KB  human nasopharyngeal epidermoid 
carcinoma cell line  
CCL-17 
HeLa human cervix adenocarcinoma cell line  CCL-2 
Neuro2A  murine neuroblastoma cell line CCL-131 
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3 METHODS AND CHARACTERIZATIONS  
3.1 Synthesis of 3-(bromomethyl)-4-methyl-2, 5-furandione 
(BrMMMan) 
The compound was synthesized following a previous protocol with slight 
modifications90. Briefly, dimethylmaleic anhydride (5.04 g, 40 mmol), N-
bromosuccinimide (14.24 g, 80 mmol), and benzoyl peroxide (200 mg, 0.83 mmol) 
were dissolved in carbon tetrachloride (CCl4, 300 mL) in a 500 mL round-bottom 
flask. The mixture was gently refluxed for 5 h. Then the reaction mixture was 
allowed to cool to room temperature, afterwards a second portion of benzoyl 
peroxide (200 mg, 0.83 mmol) was added. The mixture was refluxed for another 
5 h and then left overnight at room temperature. The solids were removed by 
filtration and washed 2 times with CCl4 (25 mL). The combined organic solutions 
were washed 2 times with water (100 mL) and one time with brine (100 mL), then 
dried over Na2SO4 and concentrated in vacuo to result in thick yellow oil. The oil 
was first purified by chromatography on a silica gel column (elution with 
petroleum ether/ethyl acetate 8:2) to obtain a crude product and then further 
purified by distilling twice using a miniature high vacuum distillation system. 
Three fractions were observed, the second fraction was collected (purity, about 
90 %) and distilled again.  A yield of the product (BrMMMan) of 1.30 g (purity, 
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about 97%) was obtained. 1H-NMR (500 MHz, CDCl3) δ(ppm) = 2.17 (s, 3H, -
CH3), 4.17 (s, 2H, -CH2-Br), 7.25 (CHCl3) (Figure 4.1-2).  
3.2 Synthesis of 3-(azidomethyl)-4-methyl-2, 5-furandione 
(AzMMMan)  
Synthesis was performed analogously as described in Maier´s paper with minor 
modifications90. 3-(bromomethyl)-4-methyl-2,5-furandione (BrMMMan, 310.5 
mg, 1.5 mmol) was dissolved in dry acetone (10 mL), afterwards sodium azide 
(105.6 mg, 1.6 mmol) was added in one portion. The mixture was stirred over 
night at room temperature. After filtering, the solvent was evaporated and the 
crude product was purified by silica gel column using hexane/ethyl acetate (7:3) 
as mobile phase. After evaporating the solvent, the product (83.6 mg, yield 33.4 %) 
was obtained. 1H-NMR (500 MHz, CDCl3) δ(ppm) = 2.22 (s, 3H, -CH3), 4.27 (s, 
2H, -CH2-N3), 7.25 (CHCl3) (Figure 4.1-3 ).  
3.3 Synthesis of Fmoc- and Boc-protected building block Fmoc-
Stp(Boc)3-OH  
The cationic building blocks Fmoc-Stp(Boc)3-OH was synthesis as described 
before111 112. Briefly, the synthesis is based on first selectively protection of the 
primary amine groups of TEPA with ethyl trifluoroacetate (Et-TFA), 
subsequently, the three remain secondary amine groups were Boc-protected by 
reaction with di-tert-butyl dicarbonate (Boc2O). The mixture was then work-up, 
filtered and dried at the high vaccum, which resulted in (TFA)2-(Boc)3-TEPA. 
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The primary groups were deprotected by incubating (TFA)2-(Boc)3-TEPA with 
aqueous NaOH containing 45 % EtOH, after alkaline hydrolysis step, (Boc)3-
TEPA is obtained. Then the two primary amines of (Boc)3-TEPA were 
asymmetrically reacted with succinic anhydride and Fmoc-OSu. The product was 
finally purified by dry column vacuum chromatography (DCVC)112. 
 
Figure 3-1. The scheme of synthesis of Fmoc-Stp(Boc)3-OH. 
3.4 Loading of a 2-chlorotrityl chloride resin with Fmoc-Lys(Boc)-
OH 
0.8 mmol of a chlorotrityl chloride resin (500 mg) were pre-swollen in DCM (5 
mL) for 10 min.  Fmoc-Lys(Boc)-OH (0.4 mmol) and DIPEA (1.2mmol) 
dissolved in DCM (dried over CaCl2) were added to the resin for 1 h. After 
removing the solvents, a mixture of 2 ml DCM, 1.5ml MeOH, and 250μl DIPEA 
was added twice for 10 min. After removing of the reaction mixture, the resin was 
washed 3 times with DCM (5 mL) and 3 times with DMF (5 mL). Some resin was 
separated for determination of the resin loading and the remaining resin was 
(TFA)2-(Boc)3-TEPA 
(Boc)3-TEPA 
TEPA 
Fmoc-Stp(Boc)3-OH 
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treated 7 times for 5 min with 20 % piperidine in DMF for removal of the Fmoc 
protection group. Deprotection was checked by a positive Kaiser test. Afterwards, 
the resin was washed 5 times with DMF and 4 times with DCM and dried in high 
vacuum. 
3.5 Loading of a chlorotrityl chloride resin with Fmoc-Cys-Trt-OH 
Loading of a chlorotrityl chloride resin with Fmoc-Cys-Trt-OH. 0.8 mmol of a 
chlorotrityl chloride resin (500 mg) were pre-swollen in DCM (5 mL) for 10min. 
Fmoc-Cys-Trt-OH (0.4 eq) and DIPEA (0.8 eq) were dissolved in DCM (dried 
over CaCl2) and added to the resin for 1 hour to obtain a low loaded resin of 0.1 
to 0.3 mmol/g. Subsequent steps were done as described above for the loading of 
a chlorotrityl chloride resin with Fmoc-Lys(Boc)-OH.   
3.6 Kaiser test  
Kaiser test was used for qualitative detection of free amino groups on the resin113. 
For this purpose a very small amount of resin beads, previously washed with DMF 
and DCM, were transferred to an Eppendorf tube. One drop of each 80 % (w/v) 
phenol in EtOH, 5 % (w/v) ninhydrin in EtOH and a solution of 0.02 mM KCN 
in pyridine were added to the Eppendorf tube and heated for 4 min at 99 °C. In 
the absence of free amino groups the beads remained colorless and the solution 
yellow (negative Kaiser Test). The presence of free amino groups was indicated 
by a blue color of the resin beads and the solution (positive Kaiser test). 
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3.7 Resin load determination  
For determination of the resin loading, 10 mg of the resin were separated from the 
main batch and dried under high vacuum. The resin was then treated with 1 mL 
deprotection solution (20 % piperidine in DMF) for 1 h, diluted 25 μl of 
supernatant in 975 μl DMF and UV absorption was measured at 301 nm. The 
blank samples were prepared as the same procedure of the sample. Finally, the 
resin loading in [mmol/ g] is obtained by the following equation: resin load 
[mmol/g] = (A*1000) / (m [mg]*7800*D). M: resin mass. A: Absorbance. 7800: 
molar extinction coefficient [L*mol-1*cm-1]. D: dilution factor. 
3.8 Synthesis of 386 and 689 
Chlorotrityl chloride resin preloaded with Fmoc-Cys-Trt-OH was used for 
synthesis of oligomers of artificial oligoamino acids (386, 689) under standard 
Fmoc solid phase peptide synthesis conditions using syringe microreactors87 111-
112. In case of 689, the coupling steps are the same as 386 except for followed by 
one more coupling with histidine after each STP coupling. Briefly, coupling steps 
were carried out using 4 eq. Fmoc-amino acid, 4 eq. HOBT, 4 eq. PyBop and 8 
eq. DIPEA in DCM/DMF (1/1, 1.5 ml: 1.5 ml) for 1 h incubation time. Fmoc 
deprotection was accomplished by 7 × 5 min incubation with 20% piperidine in 
2ml DMF. After each coupling and deprotection step a washing procedure 
comprising 3 × 1.5 ml DMF, 3 × 1.5 ml DCM incubation and a Kaiser test were 
performed113. In case of a positive result of the Kaiser test after coupling, the last 
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coupling step was repeated. In case of a negative result after deprotection, the last 
deprotection step was redone. Symmetrical branching points were introduced by 
using Fmoc-Lys(Fmoc)-OH. Finally, all peptides were cleaved off the resin by 
incubation with TFA/TIS/H2O at the ratio of 95: 2.5:2.5 (v/v/v) for 90 min. The 
cleavage solution was concentrated under reduced pressure and peptides were 
precipitated in 50 mL precooled MTBE/n-hexane (1:1 v/v). All oligomers were 
purified by size exclusion chromatography using an Äkta purifier system (GE 
Healthcare Bio-Sciences AB, Uppsala, Sweden) based on a P-900 solvent pump 
module, a UV-900 spectrophotometrical detector, a pH/C-900 conductivity 
module, a Frac-950 automated fractionator, a Sephadex G-10 column and 10 mM 
hydrochloric acid solution–acetonitrile 7:3 as solvent. If necessary, additional 
purification was carried out by preparative RP-HPLC using a VWR LaPrep 
system and a Waters Symmetry Prep C18 column (7 µm, 19×150 mm). All 
peptides were lyophilized. The presence of the different elements of the oligomer 
sequences was validated by 1H-NMR. The purity of the oligomers was 
investigated by RP-HPLC. 
3.9 Synthesis of folate-PEG28-lysine 
2-Chlorotrityl chloride resin preloaded with Fmoc-Lys(Boc)-OH was used for the 
synthesis of PEGylated folate conjugates by solid phase synthesis114 115. The 
protected Fmoc-PEG28-OH, Fmoc-Glu-OtBu and N-(trifluoroacetyl) pteroic acid 
were coupled to deprotected α-amine of the resin-bound lysine using 4 equiv 
amino acid, 4 equiv HOBT, 4 equiv PyBop, and 8 equiv DIPEA in DCM/DMF 
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and 1 h incubation time. Fmoc deprotection was carried out by 7 ×5 min 
incubation with 20% piperidine in DMF and twice with 20% piperidine containing 
2% DBU. After each coupling and deprotection, resin was washed three times 
with DMF and DCM, and a Kaiser test113 was performed. After completion of the 
coupling, the resin was washed with DMF, DCM, n-hexane and then dried in 
vacuo. Afterwards, the conjugate was cleaved from the resin by incubation with 
TFA/TIS/H2O at the ratio of 95: 2.5:2.5 (v/v/v) for 90 min. Concentration of the 
filtered solution under reduced pressure and precipitation of the conjugate in 50 
mL precooled MTBE/n-hexane (1:1 v/v) followed. After centrifugation, the 
supernatant was discarded and the precipitated conjugate was purified by size 
exclusion chromatography using an ÄKTA purifier system (GE Healthcare Bio-
Sciences AB, Uppsala, Sweden) based on a P-900 solvent pump module, a UV-
900 spectrophotometric detector, a pH/C-900 conductivity module, a Frac-950 
automated fractionator, a Sephadex G10 column (diameter 10 mm, length 60 mm), 
and 10 mM hydrochloric acid/acetonitrile 7:3 as solvent. The collected fractions 
were lyophilized and analyzed by 1H NMR. 
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Figure 3-2.1H NMR of lysine-PEG28-folate. 
 
3.10 Synthesis of 689 (386)-Mal-PEG4-DBCO 
Oligomer 689 (HCl salt, MW = 6038.4 g/mol, 3 mg, 0.5 μmol) was dissolved in 
0.9 mL of Hepps (pH = 8.5); afterward, DBCO-PEG4-Mal (1 mg, 1.5 μmol) 
dissolved in 100 μL of DMSO was slowly added, and the mixture was reacted for 
1 h under constant shaking (800 rpm) at 20 °C. Then this solution was directly 
used for conjugation with EGFP-AzMMMan or RNase A-AzMMMan (Figure3-
3). The 386-AzMMMan was synthesized in an analog way using 2 mg of 386 
(HCl salt, MW = 3955.2 g/mol, 0.5 μmol) and 1 mg of DBCO-PEG4-Mal (1.5 
μmol). 
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Figure 3-3. Illustration of protein modification and subsequent traceless release using the pH 
responsive AzMMMan linker. AzMMMan, azidomethyl-methylmaleic anhydride; 
DBCO,dibenzylcyclooctyne;  SPAAC, strain-promoted alkyne-azide cycloaddition. 
3.11 Synthesis of folate-PEG28-lysine-DBCO 
Folate-PEG28-lysine (5 mg, 2.7 μmol) was dissolved in a 400 μL mixture of Hepps 
(0.5 M, pH 8.5) and DMSO (1:1 v/v). Subsequently, DBCO NHS ester (1.25 mg, 
3.1 μmol) diluted in DMSO (100 μl) was added and reacted for 2 hours under 
constant shaking (800 rpm, 20 °C).The mixture was purified by dialysis against 5 
L PBS using dialysis membrane with a MWCO of 800Da (Carl Roth, Karlsruhe, 
Germany) and then was harvested. The product was then adjusted to a volume of 
3 ml and stored in the freezer (-80 oC) for following reactions.  
 
Figure 3-4. The chemical structure of folate-PEG28-lysine-DBCO. 
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3.12 Synthesis of INF7-Mal-PEG4-DBCO 
The thiol group of INF7 peptide was used for conjugation with the maleimide 
group of DBCO-PEG4-Mal. Briefly, INF7 (5mg, 1.78 μmol) was dissolved in PBS 
(pH 7.4), using NaOH (0.5M) solution to adjust the pH to 7.4. Then DBCO-PEG4-
maleimide (1.1mg, 1.61 μmol) was added and reacted for 1 hour under constant 
shaking (800 rpm, 20 °C). The solution was stored in the freezer (-80 oC) and used 
for following reactions. MALDI MS data are displayed in the following. 
 
Figure 3-5. a) The chemical structure of INF7-Mal-PEG4-DBCO.  b) MALDI-MS of INF7-
Mal-PEG4-DBCO (3362.008). MALDI MS was carried out by Stephan Morys (PhD study, 
Department of Pharmacy, LMU). 
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3.13 Expression and purification of nlsEGFP  
Recombinant nlsEGFP was produced as previously reported90. Briefly, E.coli 
bacterial strain BL21(DE3)plysS, transformed with a pET23a(+) plasmid 
containing the nlsEGFP gene construct were grown to an optical density of 0.75 
(600 nm) under constant shaking in TB medium (37 °C). Protein expression was 
induced by addition of IPTG to a final concentration of 1 mM and incubation was 
continued for 16 hours at 32 °C. The cells were harvested at 4000 rpm by 
centrifugation. After ultrasonic cell lysis, the EGFP containing a polyhistidine tag 
was purified by nickel chromatography using a gradient from binding buffer (50 
mM sodium hydrogen phosphate, 300 mM sodium chloride, 20 mM imidazole) 
to elution buffer (50 mM sodium hydrogen phosphate, 500 mM sodium chloride, 
250 mM imidazole). The protein was dialyzed (MWCO 14000) over night at 4 °C 
against phosphate buffered saline (PBS) buffer (pH 7.3). 
3.14 Synthesis of EGFP-AzMMMan 
The modification of nlsEGFP with AzMMMan was carried out as reported 
before90. Briefly, nlsEGFP (5 mg, 0.16 μmol) was dissolved in Hepps buffer (950 
μL, 0.5 M, pH=9.0). Afterwards AzMMMan (5 mg, 30 µmol) was diluted in 
acetonitrile (50 μL) and dropped slowly to the protein solution. Subsequently the 
mixture was incubated for 2 hours under constant stirring (800 rpm) at 20 °C and 
then purified by size exclusion chromatography (SEC) using Sephadex G25 
material, PBS 8.0 as mobile phase. The concentration of EGFP-AzMMMan was 
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quantified photometrically (extinction coefficient of 55000 M-1cm-1 at 488 nm). 
AzMMMan modified EGFP was snap frozen by liquid nitrogen and stored in the 
freezer (-80 oC). 
3.15 Synthesis of EGFP-AzMMMan-DBCO-PEG4-Mal-689 and -
386 
Protein conjugates were synthesized by copper free click chemistry (Figure 3-3). 
Briefly, four parts of EGFP-AzMMMan (0.25 mg, 7.90*10-3 μmol) were 
separately dissolved in Hepps (pH=8.5), subsequently reacted with the cationic 
oligomer (DBCO-PEG4-Mal-689) at various molar ratios (molar ratios of 689: 
EGFP=2, 4, 8, 16) for 4 h under constant shaking (800 rpm, 20 oC). Free oligomer 
was removed by dialysis (dialysis membrane MWCO 14000) against 5 L PBS 
(pH=8.0) overnight at 4 oC. The purified solution was collected and the 
concentration of EGFP-AzMMMan-DBCO-PEG4-Mal-689 was quantified 
photometrically (extinction coefficient of 55000 M-1cm-1 at 488 nm). The solution 
was snap frozen by liquid nitrogen and stored in the freezer (-80 oC). Protein 
conjugates with DBCO-PEG4-Mal-386 were synthesized analogously.  
3.16 Synthesis of EGFP -AzMMMan-DBCO-lysine-PEG28-folate 
Four batches of EGFP-AzMMMan (0.5 mg, 1.58 × 10-2 μmol) were separately 
diluted in Hepps (0.5 M, pH 8.5), and individual ratios of folate-PEG28-lysine-
DBCO (folate: EGFP =1, 5, 15, 20) were added and reacted for 4 hours under 
constant shaking (800 rpm, 20 °C). Free DBCO-lysine-PEG28-folate was removed 
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by dialysis (dialysis membrane MWCO 14000) against 5L of PBS (pH 8.0) 
overnight at 4 oC. The purified solution was collected, and the concentration of 
EGFP-AzMMMan-DBCO-lysine-PEG28-folate was quantified photometrically 
(extinction coefficient of 55 000 M−1 cm−1 at 488 nm). The solution was snap 
frozen by liquid nitrogen and stored in the freezer (−80 °C).  
3.17 Synthesis of EGFP-AzMMMan-DBCO-PEG4-Mal-INF7 
INF7 modified EGFP was synthesized similarly to last section. Briefly, four 
batches of EGFP-AzMMMan (0.5mg, 1.58×10-2 μmol) were separately diluted in 
Hepps (0.5M, pH 8.5), afterwards individual ratios of INF7-Mal-PEG4-DBCO 
(INF7: EGFP =1, 5, 15, 20) were added separately and reacted for 4 hours under 
constant shaking (800 rpm, 20 °C). Free INF7-Mal-PEG4-DBCO was removed by 
dialysis (dialysis membrane MWCO 14000) against 5L of PBS (pH 8.0) overnight 
at 4 oC. The purified solution was then collected, and the concentration of EGFP-
AzMMMan-DBCO-PEG4-Mal was quantified photometrically (extinction 
coefficient of 55 000 M−1 cm−1 at 488 nm). The solution was snap frozen by liquid 
nitrogen and stored in the freezer (−80 °C).  
3.18 Synthesis of INF7-Mal-PEG4-DBCO-EGFP-AzMMMan-
DBCO-lysine-PEG28-folate 
Briefly, four batches of EGFP-AzMMMan (0.5mg, 1.58 × 10-2 μmol) were 
diluted in Hepps (0.5M, pH 8.5), afterwards, DBCO-lysine-PEG28-folate (0.272 
mg, 0.158 μmol) was added to each protein solution and reacted for 2 hours under 
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constant shaking (800 rpm, 20 °C). Then four individual ratios of DBCO-PEG4-
Mal-INF7 (INF7: EGFP=1, 5, 10, 15) were added and the reaction mixture was 
incubated for four hours under constant shaking (800 rpm, 20 °C). The four 
different protein conjugates were purified and quantified using the same method 
as described in the last section.  
3.19 Synthesis of RNase A-Cy5  
RNase A (5 mg, 0.37 μmol) was dissolved in 900 μL PBS (pH=8.5), then NHS-
Cy5 (0.225 mg, 0.37 μmol) was dissolved in 100 μL DMSO and added to the 
protein solution. The mixture reacted for 2 hours under constant shaking at 20 oC. 
Then SEC using Sephadex G25 material and and PBS 8.0 as mobile phase was 
carried out to purify the mixture. The purified RNase A-Cy5 was used to react 
with AzMMMAn and DBCO-PEG4-Mal-689 as described below. 
3.20 Synthesis of RNase A-FITC 
RNase A (5 mg, 0.37 μmol) was dissolved in 900 μl Hepps (0.5 M, pH 8.5), then 
FITC (0.144 mg, 0.37 μmol) was dissolved in DMSO (100 μl) and added into the 
protein solution. The mixture was reacted for 2 hours under constant shaking at 
20 oC. After that, size exclusion chromatography (SEC) using Sephadex25 
material and PBS (pH 8.0) as mobile phase was carried out to purify the product. 
RNase A-FITC was filed up and concentrated. Then the purified RNase A-FITC 
was quantified by BCA assay and stored in freezer (-80 oC) and used for the 
reaction with AzMMMan as described below. 
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3.21 Synthesis of FITC (Cy5)-RNase A-AzMMMan 
RNase A-FITC (RNase A-Cy5) (3 mg) was dissolved in 500μl Hepps (0.5 M, pH 
9.0) and AzMMMan (3 mg) was dissolved in 50μl DMSO was added in to the 
RNase A-FITC (RNase A-Cy5) solution, after reacted for 2 hours, the solution 
was purified by size exclusion chromatography (SEC) using Sephadex25 material 
and PBS (pH 8.0) as mobile phase, product was filed up and concentrated, then 
was quantified by BCA and stored in freezer (-80 oC). The obtained FITC (Cy5)-
RNase A-AzMMMan was directly used for the further modification with 
oligomer (386,689) or DBCO coupled folate ligand or INF7 peptide. 
3.22 Synthesis of RNase A-AzMMMan 
RNase A-AzMMMan conjugate was prepared similarly to the EGFP-AzMMMan 
conjugate. Briefly, RNase A (5 mg, 0.37 μmol) was dissolved in 950 μL Hepps 
(0.5 M, pH=9.0) buffer, subsequently, AzMMMan (5 mg, 30 µmol)) dissolved in 
acetonitrile (50 μL) was added to the protein solution slowly, followed by 2 hours 
incubation under constant shaking at 20 oC. The mixture was purified by 
Sephadex G25 column (diameter 10 mm, length 30 mm, PBS (pH 8.0) as mobile 
phase). RNase A-AzMMMan was concentrated to 2 ml and finally quantified by 
BCA assay. Then the solution was snap frozen by liquid nitrogen and stored in 
the freezer (-80 oC). 
For quantification of amines in RNase A, which had not reacted with excessive 
AzMMMan, a TNBS assay was performed. For this purpose, a 30 mM TNBS 
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solution in 0.1 M aqueous sodium tetra borate was prepared as working solution. 
A standard curve was obtained by diluting various amounts of lysine (0.05 to 2 
μg) to 100 μl working solution in 96 well plates. Meanwhile, defined amounts of 
RNase A or RNase A-AzMMMAn were also treated with the working solution. 
Blanks were prepared in the same way by adding water to the working solution. 
After incubating at room temperature for 20 min, the absorption of samples were 
measured at 450 nm. 
3.23 Synthesis of RNase A (Cy5)-AzMMMan-DBCO-PEG4-Mal-
689 
Four batches of RNase A-AzMMMan (0.25 mg, 1.83*10-2 μmol) were dissolved 
in 900 μL Hepps (pH=8.5), afterwards various equivalents of DBCO-PEG4-Mal-
689 (molar ratios of 689: RNase A=6, 3, 1.5, 0.75) were added to the AzMMMan 
modified protein. The mixture reacted for 4 hours under constant shaking (800 
rpm) at 20 oC. RNase A conjugate was snap frozen by liquid nitrogen and stored 
in the freezer (-80 oC). For conjugate Cy5-RNase A-AzMMMan- DBCO-PEG4-
Mal-689 (689: RNase A= 6), the synthesis steps are the same as RNase A-
AzMMMan-DBCO-PEG4-Mal-689 except for using Cy5-RNase A-AzMMMan 
to replace RNase A-AzMMMan. (Cy5-)RNase A-AzMMMan-DBCO-PEG4-
Mal-386 conjugates were synthesized analogously. 
3.24 Synthesis of RNase A-PEG28-folate 
 
RNase A-AzMMMan (1.83 × 10-2 μmol) was diluted in 150 μL Hepps (0.5 M, pH 
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8.5) and reacted with folate-PEG28-lysine-DBCO (at molar ratio of 11 or 3 for 
conjugates 1 and 2, respectively) for 4 hours under constant shaking (800 rpm, 
20 °C). Free folate-PEG28-lysine-DBCO was removed by dialysis (dialysis 
membrane MWCO 3500) against 5 L of PBS (pH 8.0) overnight at 4 oC. The 
purified solution was collected, and the concentration of RNase A conjugate was 
quantified by BCA. The solution was snap frozen by liquid nitrogen and stored in 
the freezer (−80 °C).  
The completeness of the reaction of RNase A-AzMMMan with 11 equivalents of 
folate-PEG28-lysine-DBCO in conjugate 1 synthesis was monitored by analytical 
HPLC (detection wavelength 280 nm) using a VWR Hitachi Chromaster HPLC 
system (5160 pump module, 5260 auto sampler, 5310 column oven, 5430 diode 
array detector). A Waters Xbridge C18 column (5 μm, 4.6 x 150 mm), a linear 
gradient between 0.1M TEAA buffer/acetonitrile was used for elution. The 
residual nonreacted folate-PEG28-lysine-DBCO was monitored over an analysis 
time of 45 min.  
3.25 Synthesis of FITC-RNase A-PEG28-folate 
RNase A-FITC (0.22 µmol) was dissolved in 500μl Hepps (0.5 M, pH 9.0) and 
AzMMMan (3 mg, 18 μmol) was dissolved in 50 μL DMSO and was added in to 
the RNase A-FITC solution. After incubation for 2 hours, the solution was purified 
by size exclusion chromatography (SEC) using Sephadex G25 material and PBS 
(pH 8.0) as mobile phase. The product was collected and concentrated to 1.5 ml, 
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then was quantified by BCA and stored in the freezer (-80 oC). Subsequently, two 
parts of FITC-RNase A-AzMMMan (1.83 × 10-2 μmol each) were separately 
diluted in 150 μL Hepps (0.5 M, pH 8.5), and 1 (for conjugate FITC-folate-1) or 
3 (for conjugate FITC-folate-3) molar equivalents of folate-PEG28-lysine-DBCO 
were added and reacted for 4 hours under constant shaking (800 rpm, 20 °C). Free 
folate-PEG28-lysine-DBCO was removed by dialysis (dialysis membrane MWCO 
3500) against 5L of PBS (pH 8.0) overnight at 4 oC. The dialyzed solution was 
collected, and the concentration of FITC-RNase A-PEG28-folate was quantified 
by BCA assay. The solution was snap frozen by liquid nitrogen and stored in the 
freezer (−80 °C).  
3.26 Synthesis of INF7-PEG4-RNase A-PEG28-folate 
 
Briefly, RNase A-AzMMMan (7.32 × 10-2 μmol) was diluted in 600 µL Hepps 
(0.5M, pH 8.5). Afterwards, folate-PEG28-lysine-DBCO (0.22 μmol, three molar 
equivalents) was added to the protein solution and reacted for 1 hour under 
constant shaking (800 rpm, 20 °C). The solution was divided into four equal parts. 
To each RNase A (1.83 × 10-2 μmol) solution, INF7-Mal-PEG4-DBCO at 1, 2, 4, 
8 molar equiv. for conjugates 3, 4, 5 or 6, respectively) was added. The reaction 
mixtures were incubated for further three hours under constant shaking (800 rpm, 
20 °C). The four different protein conjugates were purified by dialysis (dialysis 
membrane MWCO 3500) and quantified by BCA assay. The solutions were then 
snap frozen by liquid nitrogen and stored in the freezer (−80 °C) for following 
experiments. 
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3.27 Synthesis of RNase A-PEG4-INF7 
 
INF7 modified RNase A was synthesized similarly to last section. Briefly, RNase 
A-AzMMMan (1.83 × 10-2 μmol) was diluted in 150 µL Hepps (0.5 M, pH 8.5), 
afterwards INF7-Mal-PEG4-DBCO (at INF7: RNase A molar ratio of 8) was 
added and reacted for 4 hours under constant shaking (800 rpm, 20 °C). Free 
INF7-Mal-PEG4-DBCO was removed by dialysis (dialysis membrane MWCO 
3500) against 5 L of PBS (pH 8.0) overnight at 4 oC. The purified solution was 
then collected, and the concentration of RNase A-conjugate (7) was quantified by 
BCA. The solution was snap frozen by liquid nitrogen and stored in the freezer 
(−80 °C).  
3.28 Analytics and methods 
3.28.1 Flash column chromatography (FCC)  
Stationary phase silica gel with a mean diameter between 0.035 and 0.073 mm 
was used. Column height and diameter were varied according to sample size and 
the required resolution. 
3.28.2 Thin layer chromatography (TLC)  
Silica gel coated aluminium plates were used for thin layer chromatography. 
Detection method was UV-detection at 254 nm. 
3.28.3 1H-NMR 
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The 1H-NMR spectra was recorded at room temperature using a JNMR-GX (400 
MHz, Joel) or a JNMR-GX 500 (500 MHz) with a coupling constant of 0.3 Hz. 
All spectra were recorded without TMS as internal standard and thus spectra were 
calibrated to the residual proton signal of the deuterated solvent. For the 
measurements 10-100 mg sample were used. Spectra were analyzed using the 
NMR software MestreNova (MestreLab research). 
3.28.4 Size-exclusion chromatography (SEC) 
All oligomers and linker modified proteins were purified by size exclusion 
chromatography using the ÄKTA purifier 10 system (GE Healthcare Bio-Sciences 
AB, Uppsala, Sweden) combined with a P-900 solvent pump module, a UV-900 
UV/VIS multi-wavelength detector, a pH/C-900 conductivity module and a Frac-
950 automated fraction collector.  Sephadex G-10 or Sephadex G-25 was used as 
the gel filtration medium and PBS (pH 8.0) as elution buffer. The absorption at 
214, 260 and 280 nm was monitored and the fractions were collected, snap-frozen 
and freeze-dried.  
3.28.5 UV-Vis spectroscopy  
Concentrations of EGFP, linker, and linker modified EGFP were determined by 
measuring UV-Vis absorbance at wavelength of 488nm or broad wavelength 
(200nm-800nm). For these measurements a Genesys 10 S UV-Vis 
spectrophotometer (Thermo Scientific, Bonn, Germany) was used. 
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3.28.6 High-performance liquid chromatography (HPLC) 
The completeness of the reaction of RNase A-AzMMMan with 11 equivalents of 
folate-PEG28-lysine-DBCO in conjugate 1 synthesis was monitored by analytical 
HPLC (detection wavelength 280 nm) using a VWR Hitachi Chromaster HPLC 
system (5160 pump module, 5260 auto sampler, 5310 column oven, 5430 diode 
array detector). A Waters Xbridge C18 column (5 μm, 4.6 x 150 mm), a linear 
gradient between 0.1M aqueous TEAA buffer and acetonitrile was used for elution. 
3.28.7 SDS-PAGE of RNase A (EGFP) conjugates 
Protein samples were loaded on a 12.5% SDS-PAGE gel. The gels ran for 2 h at 
125 V. After electrophoresis, gels were stained with Coomassie solution (acetic 
acid/ethanol/H2O, 1:3:6, v/v/v and 0.3% Coomassie brilliant blue G250, w/v), 
then destained by washing with a solution of acetic acid/ethanol/H2O (1:3:6, v/v/v) 
and photographed. 
3.28.8 Release of RNase A from conjugates detected by SDS-PAGE 
Protein samples were loaded on a 12.5% SDS-PAGE gel. In case of RNase A 
release studies, conjugates were pre-incubated in an acidic disodium hydrogen 
phosphate - citric acid buffer (pH 5.0, 6.0) and PBS (pH 7.4) for 24 hours at 37 °C. 
Then the treated samples were loaded on a 12.5 % SDS-PAGE gel. The gel ran 
for 2 hours at 125V. After electrophoresis the gel was stained with coomassie 
solution (acetic acid/ethanol/water, 1/3/6, v/v/v and 0.3 % coomassie brilliant blue 
METHODS AND CHARACTERIZATIONS 
 
35 
 
G250, w/v). Then the gel was destained by washing with a solution of acetic 
acid/ethanol/H2O (1/3/6, v/v/v). 
3.28.9 Ethidium bromide assay for determination of enzymatic RNase A 
activity 
1 μL EtBr (0.5 µg/mL) was added into 997 μL PBS buffer (pH=7.4) as blank 
control, then 2 μL RNA (10 mg/mL) were added, the solution was stirred and 
fluorescence intensity was monitored during 5 min equilibration. After addition 
of RNase A samples (1 μg RNase A) the solutions were incubated under stirring 
for additional 5 min. The EtBr fluorescence was measured at the excitation 
wavelength λex=510 nm and emission wavelength λem=590 nm using a Cary 
Eclipse spectrophotometer (Varian, Germany).  
3.28.10 Erythrocyte leakage assay 
Anticoagulated human red blood cells (obtained from LMU Clinics - Campus 
Großhadern, Munich, Germany) were washed with PBS for several times. After 
centrifugation, the erythrocyte pellet was resuspended, divided into three parts 
and each diluted to 5 ×107 erythrocytes per mL with PBS at pH 7.4, 6.5 or 5.5, 
respectively. Different concentrations of RNase A conjugates, free RNase A, 
INF7-Mal-PEG4-DBCO or free INF7 were diluted in 75 μL with the PBS at the 
mentioned pH values and transferred to a V-bottom 96-well plate (NUNC, 
Denmark). Control wells were treated with 1% Triton X-100 for 100% lysis and 
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PBS at the different pH values (pH 7.4, 6.5, 5.5) as negative control without lysis. 
Afterwards, 75 μL erythrocyte suspension was added to each well, resulting in a 
final concentration of 1 μM, 2 μM, 4 μM RNase A conjugates or free RNase A, 
and 8 μM, 16 μM, 32 μM INF7-Mal-PEG4-DBCO or free INF7. The plates were 
incubated under constant shaking for 1 h at 37 °C. After centrifugation, 80 μL 
were transferred to flat bottom 96-well plates for photometric quantification of 
hemoglobin release at 405 nm with a microplate reader (Tecan Spectrafluor Plus, 
Tecan, Switzerland). Relative hemolysis was defined according to the following 
formula:   
ℎ𝑒𝑚𝑜𝑙𝑦𝑠𝑖𝑠(%) =  
𝐴405(𝑐𝑜𝑛𝑗𝑢𝑔𝑎𝑡𝑒 𝑡𝑟𝑒𝑎𝑡𝑒𝑑) − 𝐴405(𝑃𝐵𝑆 𝑡𝑟𝑒𝑎𝑡𝑒𝑑)
𝐴405(𝑇𝑟𝑖𝑡𝑜𝑛 𝑋 𝑡𝑟𝑒𝑎𝑡𝑒𝑑) − 𝐴405(𝑃𝐵𝑆 𝑡𝑟𝑒𝑎𝑡𝑒𝑑)
∙ 100 
3.28.11 MALDI-MS 
One microliter of sample was spotted on a 1 μL matrix droplet consisting of SDHB 
Matrix dissolved at 10 mg/mL in 30 % acetonitrile / water. Samples were analyzed 
using an Autoflex II mass spectrometer (Bruker Daltonics, Bremen, Germany). 
300 spectra of respective probes were averaged for one sample spectrum. 
3.29 Biological testing  
3.29.1 Cell culture for folate modified proteins 
Human KB cells were cultured in folic acid free RPMI-1640 medium, 
supplemented with 10% FBS, 100 U mL−1 penicillin, 100 μg mL−1 streptomycin 
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and 4 mM stable glutamine at 37 °C in an incubator with 5% CO2 and humidified 
atmosphere. 
3.29.2 Cell culture for oligomer modified proteins 
HeLa (human cervical adenocarcinoma cells) and Neuro 2A (mouse 
neuroblastoma cells) cells were grown in Dulbecco’s modified Eagle’s medium 
(DMEM), supplemented with 10% fetal bovine serum (FBS), 4 mM stable 
glutamine, 100 U/mL of penicillin, and 100 μg/mL of streptomycin. All cells were 
cultured in an incubator at 37 °C with 5% CO2 and humidified atmosphere. 
3.29.3 Flow cytometric measurement of uptake of oligomer modified EGFP 
or RNase A-Cy5 
HeLa cells were seeded into 24-well plates at a density of 50 000 cells per well. 
After 24 h, the medium was replaced with fresh medium. Subsequently, the EGFP 
conjugates (final concentration 1μM) or the RNase A-Cy5 conjugates (final 
concentration 4 μM) were added into each well and incubated at 37 °C for 2 h. 
Then the cells were washed with 500 μL of PBS containing 1000 IU heparin per 
mL. After additional wash with PBS only, the cells were detached with 
trypsin/EDTA, diluted with PBS containing 10% FBS, harvested by 
centrifugation, and taken up in PBS containing 10% FBS. The cellular 
fluorescence was assayed by excitation of EGFP at 488 nm and detection of 
emission at 510 nm with a Cyan ADP flow cytometer (Dako, Hamburg, Germany). 
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For RNase A-Cy5 conjugates, the cellular fluorescence was assayed by excitation 
of Cy5 at 635 nm and detection of emission at 665 nm. Cells were appropriately 
gated by forward/sideward scatter and pulse width for exclusion of doublets, and 
counterstained with DAPI (4, 6-diamidino-2-phenylindole) to discriminate 
between viable and dead cells. Minimum ten thousand gated cells per sample were 
collected. Data were recorded with Summit software (Summit, Jamesville, NY). 
Analysis was done by FlowJo 7.6.5 flow cytometric analysis software. All 
experiments were performed in triplicates. 
3.29.4 Fluorescence microscopy of oligomer modified EGFP conjugates 
HeLa cells were seeded into eight-well Nunc chamber slides (Thermo Scientific, 
Braunschweig, Germany) at a density of 10 000 cells per well. After 24 h, the 
medium was replaced with fresh medium. Subsequently, the EGFP conjugates 
were added into each well (final concentration 1 μM) and incubated at 37 °C for 
24 h. Then the cells were washed with 300 μL of PBS containing 1000 IU heparin 
per mL. After additional wash with PBS only, the cells were fixed with 4% 
paraformaldehyde. Nuclei were stained with DAPI (1 μg/mL). The cells were 
observed on a Zeiss Axiovert 200 fluorescence microscope (Jena, Germany). A 
20×objective or a 40× objective and appropriate filter sets for analysis of EGFP 
and DAPI were used. Data were analyzed and processed by AxioVision Rel. 4.8 
software (Zeiss, Jena, Germany). 
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3.29.5 Flow cytometric measurement of association of folate modified EGFP 
conjugates  
KB cells were seeded into 24-well plates at a density of 50 000 cells per well. 
After 24 h, the 500 μL medium was replaced with fresh serum-containing medium. 
Then, various nlsEGFP conjugates (final concentration 0.5 μM) or nlsEGFP (final 
concentration 1.5 μM) were added into each well and incubated on ice for 45 min. 
For competition experiments with free folic acid, the KB cells were pre-treated 
with 100 μM free folic acid on ice for 30 min before adding conjugates. Then, the 
cells were washed with 500 μL PBS, detached with trypsin/EDTA and diluted with 
PBS containing 10% FBS. After centrifugation, the cells were taken up in 600 μL 
PBS containing 10% FBS. The cellular fluorescence was assayed by excitation of 
EGFP at 488 nm and detection of emission at 510 nm with a Cyan ADP flow 
cytometer (Dako, Hamburg, Germany). Cells were appropriately gated by 
forward/sideward scatter and pulse width for exclusion of doublets, and 
counterstained with DAPI (4′, 6-diamidino-2-phenylindole) to discriminate 
between viable and dead cells. Minimum ten thousand gated cells per sample were 
collected. Data was recorded with Summit software (Summit, Jamesville, NY). 
Analysis was done by FlowJo® 7.6.5 flow cytometric analysis software. All 
experiments were performed in triplicates. 
3.29.6 Flow cytometric measurement of uptake of folate modified EGFP 
conjugates  
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KB cells were seeded into 24-well plates at a density of 50 000 cells per well. 
After 24 h, the 500 μL medium was replaced with fresh serum-containing medium. 
Then, the various nlsEGFP conjugates (final concentration 0.5 μM or 2.5 μM) or 
nlsEGFP (final concentration 1.5 μM) were added into each well and incubated at 
37 °C for 45 min, followed by an incubation of 3 h in fresh media or incubated at 
37 °C for 2 h. For free folic acid competition experiments, the KB cells were pre-
treated with 100 μM free folic acid on ice for 30 min before adding conjugates. 
Then, the cells were washed with 500 μL PBS, detached with trypsin/EDTA and 
diluted with PBS containing 10% FCS. After centrifugation, the cells were taken 
up in 600 μL PBS (pH 4.0) containing 50 μg/ml Trypan blue to extinguish the 
outside fluorescence. The cellular fluorescence was assayed by excitation of 
nlsEGFP at 488 nm and detection of emission at 510 nm with a Cyan ADP flow 
cytometer (Dako, Hamburg, Germany). Cells were appropriately gated by 
forward/sideward scatter and pulse width for exclusion of doublets, and 
counterstained with DAPI (4′, 6-diamidino-2-phenylindole) to discriminate 
between viable and dead cells. Minimum ten thousand gated cells per sample were 
collected. Data was recorded with Summit software (Summit, Jamesville, NY). 
Analysis was done by FlowJo® 7.6.5 flow cytometric analysis software. All 
experiments were performed in triplicates. 
3.29.7 Fluorescence microscopy of folate modified EGFP 
KB cells or Neuro 2A cells were seeded into 8 well Nunc chamber slides (Thermo 
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Scientific, Germany) coated with collagen at a density of 10 000 cells per well. 
After 24 h, the 300 μL medium was replaced with fresh medium. Subsequently, 
nlsEGFP conjugates or nlsEGFP were added into each well (final concentration 
0.5 μM) and incubated at 37 °C for 30 min, followed by a 3 h incubation in fresh 
media. For free folic acid competition experiments, the KB cells were pre-treated 
with 100 μM free folic acid on ice for 30 min before adding conjugates. 
Afterwards, the cell nuclei were stained by Hoechst Dye 33342 (1 μg/mL). Then, 
the live cells in medium or PBS (pH 4.0) to extinguish the outside fluorescence 
were observed on a Zeiss Axiovert 200 fluorescence microscope (Jena, Germany). 
A 63× magnification DIC oil immersion objective (Plan-APOCHROMAT) and 
appropriate filter sets for analysis of EGFP or Hoechst fluorescence were used. 
Data were analyzed and processed by AxioVision Rel. 4.8 software (Zeiss, Jena, 
Germany).  
3.29.8 Cellular association of folate modified RNase A conjugates 
KB cells were seeded into 24-well plates at a density of 50 000 cells per well. 
After 24 h, the 500 μL medium was replaced with fresh serum-containing medium. 
Then, FITC-RNase A-AzMMMAn or the RNase A conjugates FITC-folate-1 and 
FITC-folate-3 (all final concentration 2 μM) were added into each well and 
incubated on ice for 45 min. For competition experiments with free folic acid, the 
KB cells were pre-treated with 400 μM free folic acid on ice for 30 min before 
adding conjugates. Then, the cells were washed with 500 μL PBS, detached with 
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trypsin/EDTA and diluted with PBS containing 10% FBS. After centrifugation, 
the cells were taken up in 600 μL PBS containing 10% FBS. The cellular 
fluorescence was assayed by excitation of FITC at 488 nm and detection of 
emission at 510 nm with a Cyan ADP flow cytometer (Dako, Hamburg, Germany). 
Cells were appropriately gated by forward/sideward scatter and pulse width for 
exclusion of doublets, and counterstained with DAPI (4′, 6-diamidino-2-
phenylindole) to discriminate between viable and dead cells. Minimum ten 
thousand gated cells per sample were collected. Data was recorded with Summit 
software (Summit, Jamesville, NY). Analysis was done by FlowJo® 7.6.5 flow 
cytometric analysis software. All experiments were performed in triplicates. 
3.29.9 Cellular internalization of folate modified RNase A conjugates 
Cellular internalization was performed as described for the cellular association 
experiment, with the following differences: the incubation was at 37 °C for 45 
min; after centrifugation, the cells were taken up in 600 μL PBS (pH 4.0) to 
extinguish the outside fluorescence.  
3.29.10 Fluorescence microscopy of folate modified RNase A conjugates 
KB cells were seeded into 8 well Nunc chamber slides (Thermo Scientific, 
Germany) coated with collagen at a density of 10 000 cells per well. After 24 h, 
the 300 μL medium was replaced with fresh medium. Subsequently, FITC-RNase 
A-AzMMMan or the RNase A conjugate FITC-folate-3 was added into each well 
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(final concentration 2 μM) and incubated at 37 °C for 2 h, followed by a 2 h 
incubation in fresh media. For free folic acid competition experiments, the KB 
cells were pre-treated with 400 μM free folic acid on ice for 30 min before adding 
conjugates. Then, the live cells were analyzed using a Zeiss Axiovert 200 
fluorescence microscope (Jena, Germany). A 63× magnification DIC oil 
immersion objective (Plan-APOCHROMAT) and appropriate filter sets for 
analysis of FITC fluorescence were used. Data were analyzed and processed by 
AxioVision Rel. 4.8 software (Zeiss, Jena, Germany).  
3.29.11 MTT assay of oligomer modified proteins 
HeLa cells or Neuro 2A cells were seeded into 96-well plates at a density of 10 
000 cells per well. After 24 h, the medium was replaced with 80 μL of fresh 
medium. Subsequently, the RNase A conjugates (final concentration 0.5; 1.0; 2.0; 
4.0 μM), RNase A-AzMMMan (final concentration 0.5; 1.0; 2.0; 4.0 μM), 
oligomers (final concentration 3.0; 6.0; 12.0; 24.0 μM), and mixture of RNase A-
AzMMMan (final concentration 0.5; 1.0; 2.0; 4.0 μM) and oligomers (final 
concentration 3.0; 6.0; 12.0; 24.0 μM) were diluted into 20 μL with PBS, added 
to each well, and incubated at 37 °C for 48 h. Afterward, MTT solution (10 μL 
per well, 5.0 mg/mL) was added. After incubation for 2 h, the medium was 
removed, and the 96-well plates were stored at −80 °C for at least 1 h. One-
hundred microliters of DMSO per well was added to dissolve the purple formazan 
product. The optical absorbance was measured at 590 nm, with a reference 
METHODS AND CHARACTERIZATIONS 
 
44 
 
wavelength of 630 nm, by a microplate reader (Tecan Spectrafluor Plus, Tecan, 
Switzerland). The relative cell viability (%) related to control wells treated only 
with 20 μL of PBS was calculated as ([A] test/[A] control) × 100. All experiments 
were performed in triplicates.  
3.29.12 MTT assay of folate modified proteins 
KB cells were seeded into collagen coated 96-well plates at a density of 10 000 
cells per well. After 24 h, the medium was replaced with 80 μL fresh medium. 
Subsequently, the RNase A conjugates 2 to 7 or the free RNase A (final 
concentrations 1 to 8 μM), the control mixture of RNase A-FolA conjugate with 
INF7 at a ratio of 1:8 (without or with dialysis) or the free INF7 (final 
concentrations 8 to 64 μM) were diluted in 20 μL of PBS, added to each well and 
incubated at 37 °C for 48 h.  Afterwards, MTT solution (10 μL per well, 5.0 
mg/mL) was added. After incubation for 2 h, the medium was removed and the 
96-well plates were stored at -80 °C for at least one hour. 100 μL DMSO per well 
were added to dissolve the purple formazan product. The optical absorbance was 
measured at 590 nm, with a reference wavelength of 630 nm, by a microplate 
reader (Tecan Spectrafluor Plus, Tecan, Switzerland). The relative cell viability 
(%) related to control wells treated only with 20 μL PBS was calculated as ([A] 
test/[A] control) × 100%. All experiments were performed in triplicates. 
Statistical Analysis.  
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The statistical significance of experiments were analyzed by the unpaired t test, p 
< 0.05 was considered statistically significant in all analyses (95% confidence 
interval). 
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4 RESULTS 
4.1 pH-Reversible cationic RNase A conjugates for enhanced 
cellular delivery and tumor cell killing 
The chapter has been partly adapted from: 
Liu X, Zhang P, He D, Rödl W, Preiß T, Rädler JO, Wagner E, Lächelt U. pH-
Reversible Cationic RNase A Conjugates for Enhanced Cellular Delivery and 
Tumor Cell Killing. Biomacromolecules. 2016 Jan 11;17(1):173-82. 
Lysine residues are convenient anchor points in proteins for synthetic 
modification by acylation. However, irreversible modification can affect the 
activity of proteins. This work is based on the formation of covalent amide bonds 
between the lysines of proteins (Enhanced Green Fluorescent Protein, EGFP; 
RNase A, Ribonucleases A) and the pH sensitive bifunctional (amine- and azide- 
reactivity) linker AzMMMan (Figure 4.1-1). The pH in the endo- and lysosomes 
(early endosomes 6.0-6.5, late endo- and lysosomes 4.5-5.5) is lower than in any 
other part of the cell64 66 116.  This unique feature can be utilized as a specific 
trigger for a dynamic response to the environment within the acidic vesicles.  
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Scheme 4.1-1. Native proteins are delivered to the cytosol via cellular uptake (I) and endosomal 
release (II) facilitated by the conjugated cationic oligomers, which get cleaved off in the acidic 
environment of the endosomes. 
By using the AzMMMan linker for conjugation, a protein vector can be designed, 
which is stably associated with the protein in the extracellular space and releases 
the cargo in a traceless fashion at the low endosomal pH after cellular uptake. The 
AzMMMan linker modified proteins (EGFP, RNase A) were conjugated with 
sequence defined cationic oligomers DBCO-PEG4-Mal-689 and -386 by copper 
free click chemistry for mediation of cellular uptake and endosomal escape 
(Figure 4.1-1).  
I 
II 
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Figure 4.1-1. Schematic illustration of preparation of a pH sensitive protein conjugate. a) 
Amino functions of the protein (EGFP, RNase A) react with AzMMMan linker; b) 3-arm 
cysteine containing oligomer reacts with DBCO-PEG4-Mal via thiol-maleimide reaction; c) 
linker modified protein couples with 3-arm oligomer via azide alkyne cycloaddition; d) cationic 
protein conjugate enters the cell. C, H and K represent the corresponding α-amino acids in one-
letter-code; STP stands for the used oligoamino acid succinoyl tetraethylene pentamine. 
4.1.1 AzMMMan linker  
Linker has been widely used to connect target macromoleculars with other kinds 
of active units which forms a complex formulation combines the functional parts 
of each constituent. But much of linkers lack characterization of traceless release 
from the target units or carrier, which could reduce the functional activity of the 
modified target units. Here a pH-labile amzide linker is synthesized90, which could 
bridge the -NH2 groups exist abundantly in almost all biological molecular, such 
as proteins. The synthesized linker could be obtained by two steps, the first step 
is from dimethylmaleic anhydride to 3-(bromomethyl)-4-methyl-2,5-furandione 
(BrMMMAn) by radical substitution reaction; the second step is a nucleophilic 
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substitution, -N3 group substitute –Br from BrMMMAn. The NMR shows pure 
final AzMMMAn linker is obtained.  
4.1.2 Synthesis of BrMMMan (3-(bromomethyl)-4-methyl-2, 5-furandione) 
 
 
 
 
 
 
Figure 4.1-2. 1H-NMR (500 MHz, CDCl3) of synthesis product BrMMMan.  δ(ppm) = 2.17 (s, 
3H, -CH3 BrMMMan, 4.17 (s, 2H, -CH2 BrMMMan), 2.07 (s, 6H, -CH3 2,3-dimethylmaleic 
anhydride, 4.27 (s, 4H, –CH2 2,3-dibromomethylmaleic anhydride), 7.25 (CHCl3). 
4.1.3 Synthesis of 3-(azidomethyl)-4-methyl-2,5-furandione (AzMMMan) 
 
 
  
 
 
Purity from NMR is 
about 98%. 
N-bromosuccinimide 
(2eq), 
benzoyl peroxide 
Purity from NMR 
is about 97%. 
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Figure 4.1-3. 1H-NMR (500 MHz, CDCl3) of synthesis product AzMMMan. δ(ppm) = 2.22 (s, 
3H, -CH3 AzMMMan), 4.28 (s, 2H, -CH2-N3 AzMMMan), 7.25 (CHCl3).  
4.1.4 Protein modifications 
The lysines of the proteins EGFP, RNase A were first reacted with an excess 
amount of AzMMMan linker in Hepps (0.5 M, pH 9.0) for 2 hours, followed by 
size exclusion chromatography to remove non-coupled linker. Successful 
AzMMMan modification of EGFP could be confirmed by UV spectroscopy, since 
AzMMMan and EGFP-AzMMMan have an intensive absorbance around 240 nm 
comparing to non-modified EGFP (Figure 4.1-4). The sequence-defined 
oligoamino amides 689 and 386 were synthesized by solid phase synthesis87 111, 
and the three contained cysteines were modified with DBCO-PEG4-Maleimide. 
The reaction of the AzMMMan functionalized proteins with DBCO-PEG4-
Maleimide-689 and -386 followed. The AzMMMan modified proteins bring in 
azide groups, which can be used for biorthogonal reaction with 
dibenzylcyclooctyne (DBCO) by strain promoted azide alkyne cycloaddition that 
enables the conjugation of two components via a stable triazole structure. By this 
means, linker modified proteins were incubated with various molar ratios of 
DBCO-PEG4-Mal-689 (molar ratios of 689: EGFP=2, 4, 8, 16; 689: RNase 
A=0.75, 1.5, 3, 6), initiating the click reaction between the DBCO group of the 
cationic conjugate and the azide group of AzMMMan modified proteins (Figure 
4.1-1). Since the used SV40nls-EGFP contains 26 and RNase A only 11 primary 
RESULTS 
 
51 
 
amines, approx. 2.7-fold higher molar ratios were used during synthesis of the 
EGFP conjugates to compensate the multiplicity. 
 
Figure 4.1-4. UV-Vis spectra of AzMMMan (incubation for 4h in Hepps pH 9.0), nlsEGFP and 
EGFP-AzMMMan. 
The conjugates were analyzed by SDS polyacrylamide gel electrophoresis to 
confirm successful assembly (Figure 4.1-5 a), b), c)). The SDS-PAGE gel reveals 
a gradual shift of the protein band toward lower migration distance with 
increasing 689/386 to protein ratio. The protein conjugate with highest 
modification ratio (689: EGFP=16 and 689/386: RNase A=6) exhibited the 
shortest migration indicating the highest molecular weight, which can be 
explained by more extensive DBCO-PEG4-Mal-689 attachment and crosslinking.  
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Figure 4.1-5. a) SDS-PAGE of 689-EGFP conjugates. M, molecular weight marker; numbers 
indicate the molar ratio of 689 to EGFP. Equal amounts (10 μg) of EGFP protein were loaded 
in each lane. b) SDS-PAGE of 689- (left) and c) 386- (right) modified RNase A, M, molecular 
weight marker, numbers indicate the molar ratio of oligomer to RNase A of the protein 
conjugates. Bare RNase A (RNase) and oligomers (386, 689) were used as controls. RNase A 
conjugate and bare RNase A samples contained 3μg of protein. Bare 689 and 386 oligomer 
samples contained 5 μg of oligomer.  
To show the cross-linking of 689-EGFP conjugates more detailed, fluorescence 
correlation spectroscopy (FCS) measurements of EGFP were performed (Figure 
4.1-6). FCS is a highly sensitive single-molecule technique for measuring 
hydrodynamic radii of fluorescent molecules or particles in highly diluted 
a) 
b) c) 
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solutions in the nanomolar concentration range117. EGFP and EGFP-AzMMMan, 
as well as the conjugates with 689 to EGFP ratios of 2 and 4, were shown to have 
hydrodynamic radii of 2−4 nm. In contrast, the samples with 689 to EGFP ratios 
of 8 and 16 showed clusters with a hydrodynamic radius above 0.1 μm. This 
indicates that large EGFP complexes are formed depending on the molar ratio of 
cross-linking three-arm oligomer. However, it has to be noted that also at the high 
ratios small particles were detected, which suggests that the conjugation approach 
results in rather heterogeneous mixtures of variably cross-linked proteins. 
 
 
Figure 4.1-6. FCS measurements. Numbers indicate the molar ratio of 689 to EGFP. 
Normalized average correlation curves show clustered (RH > 0.1 μm) 689-EGFP conjugates at 
high 689 to EGFP ratios (8, 16), whereas particle size at low ratios (2, 4) remain in the range of 
EGFP and EGFP-AzM (RH =2−4 nm). FCS were carried out by Tobias Preiß (Faculty of 
Physical, LMU). 
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4.1.5 Flow cytometry of EGFP conjugates 
EGFP was equipped with positive charge by modification with the cationic 
oligomer 689. The sequence-defined oligomer 689 contains 9 repeats of the 
artificial amino acid STP112 which exhibits positive charge at neutral pH but also 
a buffer capacity in the endolysosomal pH range, which was intended to enable 
transport of the protein into cells and the escape from endosomes by the proton-
sponge effect66, 118 119. It is hypothesized that different ratios of oligomer on the 
protein surface could influence the amount of intracellular protein transduction. 
To investigate this, the internalization of different conjugates with varied 
modification ratios into HeLa cells was investigated by flow cytometry. The 
results demonstrated that the sequence defined 3-arm cationic oligomer could 
deliver the protein into cells. As expected, increasing oligomer conjugation 
promoted the intracellular protein delivery indicated by a shift toward higher 
cellular fluorescence intensity in Figure 4.1-7.  This illustrates the importance of 
an optimization of coating degree, even when the protein is modified by the same 
carrier. 
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Figure 4.1-7.  Cellular uptake of conjugates with different 689 to EGFP molar conjugation 
ratios determined by flow cytometry. Untreated control cells are shown in red. 689: EGFP=2 
(blue), 689: EGFP=4 (yellow), 689: EGFP=8 (green), 689: EGFP=16 (brown). Experiments 
were carried out by Peng Zhang (PhD study, Department of Pharmacy, LMU).  
Having successfully demonstrated efficient cellular uptake of 689 modified EGFP, 
a comparison study between the two similar cationic oligomers 386 and 689 has 
been carried out. 386 is also a 3-arm cationic STP-based oligomer, having been 
successfully used for siRNA, DNA and protein delivery before111 120 121, but 689 
additionally contains histidines after each STP units to enhance endosomal 
buffering. The flow cytometry results show 386 and 689 oligomer modified EGFP 
being internalized into cells to comparable extent (Figure 4.1-8). In the 
extracellular environment, the pH is about 7.4 and the additional histidines in 689 
RESULTS 
 
56 
 
are not protonated. Therefore, these two oligomers mediate similar uptake of 
modified EGFP.   
 
Figure 4.1-8. Flow cytometry of cells incubated with 689 or 386 modified EGFP with the same 
molar ratio (16). HeLa cells were incubated with samples (1 µM EGFP) at 37 °C for 2 h before 
flow cytometry. Experiments were carried out by Peng Zhang (PhD study, Department of 
Pharmacy, LMU).  
4.1.6 Intracellular distribution of EGFP  
The cellular uptake and intracellular distribution of the EGFP conjugates with 
varied modification degree was further investigated by fluorescence microscopy 
(Figure 4.1-9). Since the used recombinant EGFP contains a nuclear localization 
signal (NLS), nuclear delivery after protein conjugate internalization is 
investigated. The protein conjugates (689: EGFP=4 and 689: EGFP=8) show 
successful nuclear entry, whereas the protein conjugates (689: EGFP=2 and 689: 
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EGFP=16) did not show any nuclear delivery. It is hypothesized that since ratio 2 
(689: EGFP) also mediates lower cellular uptake (Figure 4.1-10), the amount of 
accumulated conjugates with proton-sponge activity is not enough to break 
through the endosome. On the other hand, since the SV40 large T antigen NLS 
contains multiple lysines, the extensive modification in case of ratio 16, might 
affect intracellular trafficking. It concludes that the four EGFP conjugates have 
high intracellular uptake efficiency, and two optimized conjugates show 
successful nuclear delivery. 
Figure 4.1-9. Microscopy images of cells treated with different EGFP samples. First row: 
unmodified EGFP control, second row 689: GFP=4, third row, 689: GFP=8; (1): Bright field 
images; (2): EGFP fluorescence; (3): DAPI fluorescence (nuclear staining). HeLa cells were 
incubated samples (1 µM EGFP) for 24 h at 37 °C. 40× objective was used for image acquisition. 
Experiments were carried out by Peng Zhang (PhD study, Department of Pharmacy, LMU).  
In case of all four protein conjugates significant intracellular EGFP fluorescence 
could be observed (Figure 4.1-10), even the protein conjugates with negative zeta 
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potential (conjugation ratios 689: EGFP=2 and 689: EGFP=4) were efficiently 
internalized. In case of the latter protein conjugates, the cationic oligomer does 
not suffice to reverse all the negative charge of the protein into positive charge. 
Nevertheless, the attached cationic oligomer mediated transport of EGFP into 
cells. This accounts for the high potency of the used sequence-defined oligomer. 
 
Figure 4.1-10. Fluorescence microscopy of HeLa cells treated with different EGFP conjugates 
of varied molar ratios. (a) Bright field, (b) EGFP fluorescence and (c) DAPI fluorescence 
(nuclear staining). Cells were incubated with 1 µM protein solutions for 24 h. 40× objective 
was used for image acquisition. Experiments were carried out by Peng Zhang (PhD study, 
Department of Pharmacy, LMU).  
 
4.1.7 pH-responsive release of RNase A conjugates 
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 RNase A was utilized to demonstrate the feasibility of covalent modification by 
the established method with a biologically active protein. RNase A, an 
endoribonuclease, catalyzes the cleavage of the phosphodiester bond between the 
5’-ribose of a nucleotide and the phosphate group attached to the 3’-ribose of an 
adjacent pyrimidine nucleotide. The enzyme has been used as an alternative 
chemotherapy drug for clinical cancer treatment, since it can degrade intracellular 
RNA inducing apoptosis of tumor cells89. Wang recently used cationic lipid-like 
nanoparticles to coat negatively charged RNase A through electrostatic interaction, 
showing an intracellular delivery and cancer killing result71. Herein, the cationic 
vector to attach with pH-sensitive AzMMMan modified RNase A is utilized. The 
resulting protein conjugate was expected to form a more stable delivery system 
than the often used electrostatic noncovalent complexes. A series of 689 or 386 
oligocation modified RNase A conjugates was synthesized. To investigate the pH-
responsive cleavage, RNase A-AzMMMan-DBCO-PEG4-Mal-689/386 were 
incubated (molar conjugation ratio of 689 or 386 to RNase A = 6) at neutral or 
acidic pH and the release of free RNase A was monitored by SDS-PAGE (Figure 
4.1-11). The gel demonstrated that incubation for 24 hours at pH 5 resulted in 
significant protein release, in contrast to incubation in PBS buffer at pH 7.4 where 
almost no cleavage of RNase A could be observed.  
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Figure 4.1-11. pH dependent traceless release of RNase A from protein conjugates (molar 
conjugation ratio 6). M, molecular weight marker; 1) 689 modified RNase A incubated in 
citrate-phosphate buffer (pH=5) for 24 h at 37 oC; 2) 689 modified RNase A incubated in PBS 
(pH=7.4) for 24 h at 37 oC ; 3) 689 modified RNase A without any treatment;  4) 386 modified 
RNase A incubated in citrate-phosphate buffer (pH=5) for 24 h at 37 °C;  5) 386 modified 
RNase A incubated in PBS (pH=7.4) for 24 h at 37 oC ; 6) 386 modified RNase A without any 
treatment. Equal amounts (3 μg) of RNase A were loaded in each lane. 
4.1.8 Ethidium bromide assay for determination of enzymatic RNase A 
activity 
For detecting the enzymatic activity of RNase A and its conjugates, an ethidium 
bromide (EtBr) fluorescence assay (Figure 4.1-12, 4.1-13) is developed. The 
fluorescence intensity of a solution containing 0.5 ng EtBr and 20 µg RNA in 1 
mL PBS (pH=7.4) was monitored during an equilibration time of 5 min. After 
addition of RNase A samples, the decrease of fluorescence intensity based on the 
enzymatic RNA degradation was monitored over 5 min.  
M       1              2           3          4             5          6            7 
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While unmodified RNase A solutions which were incubated for 24 h at pH 7.4, 
pH 5 or freshly prepared did not exhibit remarkable differences (Figure 4.1-12, 
left), the enzymatic activity of RNase A-AzMMMan conjugates was strongly 
dependent on the pH during the pre-incubation phase. RNase A-AzMMMan-386 
(Figure 4.1-12, middle), -689 (Figure 4.1-12, right) and RNase A-AzMMMan 
(Figure 4.1-13, left) revealed extremely low activity after a 24 h incubation phase 
at pH 8.5, whereas activity was restored after incubation at pH 5, indicating the 
pH-responsive release of unmodified RNase A. After 24 h incubation at pH 7.4, 
an intermediate activity was observed which obviously is caused by partial 
AzMMMan cleavage. In contrast, stable amidation of RNase A by bifunctional 
SMCC linker reduced the enzymatic activity in an irreversible, pH-independent 
fashion (Figure 4.1-13, right).  
 
Figure 4.1-12. a) Enzymatic activity of RNase A measured by an ethidium bromide assay. 
Unmodified RNase A (left), RNase A-AzMMMan-DBCO-PEG4-Mal-386 (molar ratio 6, 
middle) and RNase A-AzMMMan-DBCO-PEG4-Mal-689 (molar ratio 6, right) under different 
conditions. First row, incubated in citrate-phosphate buffer (pH=5) for 24 hours at 37 °C; 
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second row, incubated in PBS (pH=7.4) for 24 hours at 37 °C; third line, fresh solutions of 
unmodified RNase A (left), 386 (middle) and 689 conjugates (right) without incubation.  
 
Figure 4.1-13. Enzymatic activity of RNase A conjugates determined by an ethidium bromide 
assay. Activity of pH-cleavable RNase A-AzMMMan (left) and irreversible conjugate RNase 
A-SMCC (right) were investigated after different treatments. First line, incubated in buffer 
(pH=5) for 24 hours at 37 oC; second line, incubated in PBS (pH=7.4) for 24 hours at 37 oC; 
third line, samples stored in Hepps (pH=8.5) without additional treatment. RNase A-SMCC 
was synthesized analogously to RNase A-AzMMMan but with use of SMCC (Thermo 
Scientific) instead of AzMMMan. 
 
4.1.9 Cytotoxic potency of RNase A conjugates 
To verify that the covalently modified therapeutic protein can be successfully 
delivered into the cytoplasm, cell viability assays (MTT) were performed with the 
two series of oligomer (689 and 386) modified RNase A to investigate the 
biological activity and effect on tumor cell viability. As shown in Figure 4.1-14a, 
all RNAse A conjugates revealed some cytotoxicity, while the control RNase-
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AzMMMan did not induce any obvious inhibition of metabolic activity. For the 
same series (689 or 386) oligomer modified RNAse A, the toxicity increased with 
the degree of oligomer conjugation. When treated at the same ratio (0.75, 1.5, 3, 
6 μM) of two covalently modified RNase A conjugate at the same concentration, 
oligomer 689 modified RNase A showed higher toxicity than 386 oligomer 
modified RNase. Considering Figure 4.1-8, which shows that 386 and 689 
modified proteins possess similar cellular internalization at the same modification 
degree, this possibly can be explained by an enhanced endosomal escape due to 
the increased buffer capacity of the histidine-rich oligomer 689, which could 
promote an improved proton sponge effect resulting in higher toxicity of 689 
modified RNase A. Flow cytometry experiments with the most toxic protein 
conjugates (molar ratio, 689: RNase A=6, 386: RNase A=6) have been carried out 
to verify their internalization. The results shown in Figure 4.1-14b confirm again 
that 689 and 386 show similar uptake ability, consistent with Figure 4.1-8 and our 
former study. Considering the cellular uptake results, the differential activity 
possibly can be explained by an enhanced endosomal escape due to the increased 
buffer capacity of the histidine-rich oligomer 689, which could promote an 
improved proton sponge effect resulting in higher toxicity of 689 modified RNase 
A87 122. 
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Figure 4.1-14. Cellular uptake and cytotoxic potency of RNase A conjugates.  a) Viability of 
HeLa cells (MTT) after treatment with 4 μM of 386 RNase A conjugates (left bar) or 689 RNase 
A conjugates (right bars) with different oligomer. RNase A molar ratios (0.75, 1.5, 3, 6). b) 
Cellular uptake of 4 μM 386- or 689-modified RNase A-Cy5 (oligomer: RNase A molar ratio 
6). Experiments were carried out by Peng Zhang (PhD study, Department of Pharmacy, LMU).  
Finally, to demonstrate that the process of cell killing is dependent on the protein 
concentration, various amounts of 386 and 689 modified RNase A conjugates (0.5 
μM, 1 μM, 2 μM, 4 μM) as well as control groups (oligomers 386, 689; RNase A-
AzMMMan, RNase A-AzMMMan + free 689) were incubated with HeLa cells 
for 48 hours. Figure 4.1-15a reveals that cells treated with RNase A-AzMMMan-
DBCO-PEG4-Mal-689 show significantly decreased cell viability. Cells have only 
19% survival rate when treated by 4.0 μM RNase A conjugate, while cells treated 
with 0.5 μM do not seem to be affected. This accounts for the dose-response 
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correlation between cytotoxicity and added concentration of the RNase A 
conjugate. Cells treated only with RNase A-AzMMMan, 386 or 689 oligomer 
alone do not show remarkable reduction of cell viability. Likewise, the mixture of 
RNase A-AzMMMan and oligomer 689 did not decrease cell viability below 80%, 
but showed slightly higher cytotoxicity than RNase A-AzMMMan alone. This 
could be explained by electrostatic binding between negatively charged RNase A-
AzMMMan and positively charged 689 which may result in delivery of a very 
small amount of RNase A-AzMMMan into the cytoplasm, inducing slightly toxic 
effects.  
 
 
 
 
 
 
 
 
 
a) 
b) 
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Figure 4.1-15. Cytotoxic potency of RNase A conjugates a) Viability of HeLa cells (MTT) 
after treatment with 386-RNase A, 689-RNase A conjugates (molar ratio 6) and control groups 
(bare 386, bare 689, RNase-AzMMMan, mixture of 689 and RNase A-AzMMMan) at various 
concentrations. Concentration of RNase A conjugates, RNase A-AzMMMan, and 
oligomer/RNase A control mixtures (from left to right): 0.5 μM, 1.0 μM, 2 μM, 4 μM. 
Concentration of bare oligomers 386 and 689: 3.0 μM, 6.0 μM, 12 μM, 24 μM. b) Viability of 
N2A cells (MTT) after treatment with 689 modified RNAse A conjugates (molar ratio 6) under 
the same conditions as described in c). Experiments were carried out by Peng Zhang (PhD study, 
Department of Pharmacy, LMU).  
Interestingly, when cells were treated with the same concentration of 386- and 
689- modified RNase A, 689-modified RNase A always showed higher 
cytotoxicity than 386-modified RNase A (viability 40% compared to 78% at 2 
μM, 19% compared to 49% at 4 μM. We hypothesize that both protein conjugates 
have the same intracellular delivery ability as a result of same protonation degree 
at extracellular pH, which is provided by the Figure 4.1-8 and Figure 4.1-14b. 
However, after cellular uptake and entering into endosomes, as the pH drops from 
7.4 to 6.0, the histidines of 689 could promote the proton sponge effect and 
endosomal escape resulting in more efficient protein delivery into the cytoplasm. 
The potency of the 689 modified RNase A to kill cancer cells is not restricted to 
HeLa is also further demonstrated. MTT assays of murine neuroblastoma N2A 
cells incubated with the most potent RNase A conjugate also showed dose 
dependent tumor cell killing (Figure 4.1-15b). 
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4.2 Intracellular delivery of EGFP by combination of targeting 
ligand and endosomal escape lytic peptide 
In the last section work, a polymer was utilized to function as the carrier for 
protein delivery which exhibits very high delivery efficiency, as well as 
demonstrated successfully to restore its biological activity during modification 
and then release its full biological function after traceless cleavage in the 
endosomal acidic environment. But this system employed the cationic units as the 
intracellular part, this is not stable in the bloody conditions of the organic, which 
in rich of all kinds enzymatic degradation and salts. In this section, a 
multifunctional delivery system, combining a targeting ligand and an endosomal 
escape lytic peptide, is designed. No polymer is used in this strategy to avoid the 
electrostatic of the polymer carriers with the abundant macromolecular 
environment in the organics. EGFP first reacted with AzMMMan linker, and then 
DBCO coupled folate and INF7 were used to modify with the linker modified 
EGFP, as showed in Figure 4.2-1. 
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Figure 4.2-1. Schematic illustration of synthesis of target-protein-endosomal escape peptide 
conjugates.  Proteins modified by acidic traceless linker AzMMMan and coupled with target 
ligand folate and endosomal disruptive peptide INF7 by copper free click chemistry. m, n 
represents the repeat units of folate and INF7 ligand respectively.  
Based on this strategy, a series of further EGFP conjugates were synthesized as 
displayed in Table 1. 
EGFP-AM: 
DBCO-lysine-PEG28-
folate 
1:1 (1) 1:5 (2) 1:10 (3) 1:20 (4) 
EGFP-AM: 
INF7-Mal-PEG4-DBCO 
1:1 (5) 1:5 (6) 1:10 (7) 1:20 (8) 
EGFP-AM: 
folate-PEG28-lysine-
DBCO: INF7-Mal-
PEG4-DBCO 
1:10:1 
(9) 
1:10:5 
(10) 
1:10:10 
(11) 
1:10:1
5 (12) 
1:20:5 
(13) 
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4.2.1 Cellular association of EGFP-folate conjugates 
Flow cytometry was used to investigate the interaction between EGFP conjugates 
and target cells and to evaluate the impact of contained folate ligand on the cellular 
association (Figure 4.2-1). Folic acid receptor positive KB cells were incubated 
with the four different EGFP conjugates (0.5 μM) and original EGFP (1.5 μM). 
In a control experiment, preincubation with free folic acid (100 µM) was carried 
out to inhibit receptor interaction by excessive competition. As expected, 
unmodified EGFP could not bind to or be internalized into KB cells, similar to 
folate containing EGFP conjugates after the receptor block by free folic acid. In 
contrast to the control groups, the cells incubated with folate conjugates show 
distinct increase of fluorescence indicating the association with EGFP, and the 
effect increases with the ratio of folate ligand to EGFP. As expected, conjugate 4 
shows the highest cellular binding ability compared to conjugates 1, 2, 3 with 
lower ratio of contained folate. The results demonstrated that the amount of folate 
ligand connected to the protein, determined the binding ability of the final protein 
conjugates. 
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Figure 4.2-1. Cellular association of EGFP conjugates. Red: Blank control without EGFP; Blue: 
1.5 μM EGFP was added; Brown: Folate blocked for 30 min before EGFP conjugates were 
added; Green: 0.5 μM Conjugates. Incubation for 45 min. Experiments were carried out by 
Peng Zhang (PhD study, Department of Pharmacy, LMU).  
4.2.2 Cellular uptake of EGFP-folate conjugates 
The investigation of cellular uptake by flow cytometry resulted in similar findings 
as the cellular association experiments. KB cells pretreated with free folic acid 
did not show increased fluorescence intensity after incubation with EGFP 
conjugates, and conjugate 4 achieved highest cellular internalization among all 
four EGFP conjugates. In general, the levels of cellular uptake were much lower 
than association which is reasonable since receptor binding is a mandatory 
prerequisite for the receptor-mediated endocytosis of this kind of protein vectors. 
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In additional, considering from the structure point of conjugates, spacer PEG28 
anchoring between protein and folate ligand increased the distance from target 
sites of cells to protein resulting in a weakening interaction between folate and 
protein. In addition, the relative dimensions of EGFP compared to low molecular 
weight folic acid as the native substrate for endocytotic uptake via folic acid 
receptor could be responsible for restricted internalization despite successful 
receptor binding.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2-2. Cellular uptake of EGFP-folate conjugates. Red: Blank control without EGFP; 
Blue: 1.5 μM EGFP was added; Brown: Blockade of folate receptor by free folate added for 30 
min before EGFP conjugates were added; Green: 0.5 μM conjugates. Experiments were carried 
out by Peng Zhang (PhD study, Department of Pharmacy, LMU).  
4.2.3 EGFP modification with INF7-DBCO 
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Four different EGFP-INF7 conjugates at different ratios (conjugate 5, 6, 7, 8; 
DBCO-PEG4-Mal-INF7: EGFP-AzMMMan=1, 5, 10, 20, Table 1) were 
synthesized, the conjugates were analyzed by SDS polyacrylamide gel 
electrophoresis (SDS-PAGE) to verify successfully coupling. SDS-PAGE (Figure 
4.2-3, left) revealed a gradual blurry shadow of the protein conjugates band in 
contrast to the band of unmodified EGFP. This could be explained by more INF7 
being attached to EGFP with increasing ratio of INF7 to EGFP. In addition, four 
kinds of INF7-EGFP-folate conjugates were synthesized (conjugate 9, 10, 11, 12; 
EGFP: folate: INF7=1:10:1, 1:10:5, 1:10:10, 1:10:15, Table 1). Here, SDS-PAGE 
(Figure 4.2-3, right) showed similar results as for conjugates 5, 6, 7 and 8. Briefly, 
the migration distance of the conjugates (9, 10, 11, 12) decreased with the ratio of 
INF7 to EGFP (INF7: EGFP=1, 5, 10, 15), which indicates more INF7 were 
attached to EGFP when higher ratios of INF7 were used during synthesis. 
Figure 4.2-3. SDS-PAGE of EGFP-INF7 and folate-EGFP-INF7 conjugates. 5 μg of EGFP 
were loaded respectively. M, protein mark, C, EGFP control, 5-12 conjugates respond to 
conjugates in Table 1. 
4.2.4 Cellular internalization of EGFP-INF7 and folate-EGFP-INF7 
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Then the interaction of cell membrane and INF7, a kind of endosomal escape 
peptide is studied. The pH-dependent lytic peptide is derived from the amino 
terminal sequence of influenza hemagglutinin HA2 and is able to disrupt 
liposomes, erythrocytes and endosomal membranes of cells in the acidic 
environment109. The intracellular transduction of EGFP-INF7 (5, 6, 7, 8) and 
folate-EGFP-INF7 (9, 10, 11, 12) conjugates were analyzed by flow cytometry. 
EGFP-INF7 conjugates showed moderate internalization into KB cells (Figure 
4.2-4) and a slightly positive correlation with increasing degree of INF7 peptide 
modification could be observed. Conjugate 8 mediated the highest intracellular 
EGFP fluorescence though still at very low level. This could be explained by the 
pH-dependance of INF7 peptide which does not reach its full membrane 
interactive potential at pH 7.4 in the extracellular culture medium. In contrast to 
the mere INF7 modified protein conjugates, EGFP modified with both folate 
ligand and INF7 showed much higher uptake quantified by flow cytometry, and 
all four conjugates (9, 10, 11, 12) mediated similar intracellular EGFP 
fluorescence levels consistent with the same amount of folate targeting ligand. 
Taking these together (flow cytometry of conjugates 1-12), the folate ligand could 
successfully be coupled to EGFP and mediated internalization of the EGFP into 
folic acid receptor positive KB cells. Meanwhile, INF7 in normal pH (7.4) shows 
an only slightly disruptive ability of cell membrane. 
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Figure 4.2-4. Cellular internalization of EGFP-INF7 and folate-EGFP-INF7 conjugates 
measured by flow cytometry. Conjugate 5-8, EGFP-INF7 conjugates, conjugate 9-12, folate-
EGFP-INF7 conjugates. Experiments were carried out by Peng Zhang (PhD study, Department 
of Pharmacy, LMU).  
4.2.5 Traceless modification of EGFP conjugate 
Since conjugate 4 showed the highest binding and internalization, it was chosen 
to be further modified with DBCO-PEG4-Mal-INF7, which results in conjugate 
13 (table 1). The shift distance from SDS-PAGE gel indicates the EGFP-
AzMMMan (Figure 4.2-5, band 2) was successfully coupled with DBCO-lysine-
PEG28-folate (band 3), and then modified by DBCO-PEG4-Mal-INF7 (conjugate 
13, band 4).  To investigate the pH-responsive cleavage, conjugate 13 was 
incubated at neutral or acidic pH and the release of EGFP was monitored by SDS-
PAGE (Figure 4.2-5). The gel demonstrated that incubation for 24 hours at pH 5 
resulted in significant protein release but not at the point of unmodified EGFP, in 
         5           6             7            8                                    9          10          11         12 
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contrast to incubation in PBS buffer at pH 7.4 where almost no cleavage of trait 
could be observed.  
 
 
Figure 4.2-5. 1: Mark; 2: EGFP-AM; 3: EGFP-AM-folate; 4: EGFP-AM-folate(INF7) 1:20:5; 
5: EGFP-AM-folate(INF7) 1:20:5 incubated in pH 5.0 buffer at 37 oC for 24 h 6: EGFP-AM-
folate(INF7) 1:20:5 incubated in PBS (pH 7,4) buffer at 37 oC for 24 h. 
To find if some irreversible reaction happened between the uncoupled –NH2 
group from EGFP-AzMMMan and uncouple -maleimide group from DBCO-
PEG4-Mal with INF7, a higher ratio of INF7 was used to avoid reaction of 
maleimide group with -NH2 (Figure 4.2-6, band 4), as well as 2-mercaptoethanol 
was applied to quench the reactive group maleimide group (Figure 4.2-7, band 6) 
shows similar trend as Figure 4.2-5 (INF7: DBCO-PEG4-Mal=1:1, band 4). All 
these demonstrated the high reactive efficiency of click chemistry between DBCO 
group and –N3 from linker, and no obvious irreversible reaction between –NH2 
and maleimide group.  
1        2            3           4            5              6   
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Figure 4.2-6. 1: Mark; 2: EGFP-AM; 3: EGFP-AM: folate-DBCO=1:20 4: EGFP-AM: folate-
DBCO:INF7-Mal-PEG4-DBCO=1:20:5, standard steps as usual, except for  using 1.1 eq of 
INF7 to DBCO-PEG4-Mal; 5: EGFP-AzMMMan: folate-DBCO: INF7-Mal-PEG4-
DBCO=1:20:5 incubated in pH 5.0 buffer at 37 oC for 24 h. 
 
 
Figure 4.2-7. 1: Mark; 2: EGFP; 3: EGFP-AzMMMan; 4: conjugate EGFP-AM: folate: 
INF7=1:20:5, standard steps as usual, purified by dialysis (dialysis membrane MWCO 14000); 
5: same conjugate as 1, but no purification; 6: conjugate: EGFP-AM: folate: INF7=1:20:5, 
standard steps as usual, except for after the reaction of INF7 with DBCO-PEG4-Mal, 20eq of 
2-mercaptoethanol was added to quench Mal-PEG4-DBCO, and purified by dialysis (dialysis 
membrane MWCO 14000). 7: same conjugate as 13, but no purification; 8: conjugate 13 
incubated in buffer (pH 4.0); 9: conjugate 13 incubated in buffer (pH 4.0).  
A mixture of EGFP, DBCO-folate, DBCO-INF7 was prepared, both the mixture 
    1           2               3            4              5 
1      2      3        4      5      6      7       8           9 
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and original EGFP were loaded on the SDS-PAGE (Figure 4.2-8). The gel shows 
almost no difference. This also indicates AzMMMan linker could bridge the 
EGFP and DBCO-folate (INF7) by click chemistry with a covalent bond. 
 
 
 
 
 
 
 
Figure 4.2-8. M, mark;  Mix, EGFP mix with folate-DBCO for 1 hour and then mix with 
DBCO-PEG4-Mal-INF7 for another 3 hours, the same steps as for EGFP-AM-folate (INF7) 
conjugates.    
4.2.6 Intracellular distribution of EGFP  
Then conjugate 13 was chosen as a candidate (conjugate 13, EGFP: folate: 
INF7=1:20:5, Table 1) for visualization of EGFP transduction into cells by 
fluorescence microscopy (Figure 4.2-9). In an experiment where KB cells were 
pretreated with free folic acid for 30min and then incubated with the protein 
conjugate 13, no intracellular transduction could be observed (Column 1, Figure 
4.2-9). As a result of pre-incubation with folic acid, the receptor has been blocked 
and the interaction of conjugate 13 with KB cells could be competitively inhibited. 
Folic acid receptor negative N2A cells incubated with conjugate 13 also did not 
     M      EGFP    Mix 
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show intracellular fluorescence, since the uptake mechanism is a receptor 
mediated endocytosis (Column 4, Figure 4.2-9). In contrast, KB cells incubated 
with conjugate 13 and washed with PBS (pH 4.0) to quench fluorescence of EGFP 
conjugates attached to the outer cell surface showed significant intracellular 
EGFP levels (Column 3, Figure 4.2-9). The homogenous distribution EGFP in the 
whole cells, indicates successful internalization and some kind of endosomal 
escape of conjugate 13.  
 
 
 
 
 
 
 
 
 
Figure 4.2-9. Microscopy images of cells treated with conjugate 13 (EGFP: folate: 
INF7=1:20:5) at different conditions.  Column 1: KB cell blocked by 100 μM folate for 30min 
and then incubated with 0.5 μM EGFP conjugate; Column 2:  KB cell incubated with 0.5 μM 
EGFP; Column 3:  KB cell incubated with 0.5 μM EGFP conjugate and then incubated by PBS 
(pH 4) to quench the extracellular fluorescence of EGFP conjugates; Column 4:  N2A cells 
incubated with 0.5 μM EGFP conjugate. Experiments were carried out by Peng Zhang (PhD 
study, Department of Pharmacy, LMU).  
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4.3 Traceless bioreversible RNase A conjugates with PEG shielding, 
folate receptor targeting and endosomal escape domains for 
intracellular delivery 
 
The chapter has been partly adapted from: 
Liu X, Zhang P, Rödl W, Maier K, Lächelt U, Wagner E. Towards artificial 
immunotoxins: traceless reversible conjugation of RNase A with receptor 
targeting and endosomal escape domains. Submitted. 
 
In the last section, EGFP covalently modified by folate targeting ligand and INF7 
lytic peptide and showed successfully intracellular delivery. Herein, this strategy 
is applied for the delivery of a cytotoxic protein RNase A for cancer cell killing.   
4.3.1 Traceless conjugation strategy 
In this work, a multifunctional delivery strategy (Figure 1) to achieve receptor-
specific intracellular delivery of antitumoral RNase A is developed, by a pH-
responsive traceless and combined functionalization with targeting ligands (folate) 
and endosomal escape peptides (INF7). The amino group of the targeting ligand 
reagent (lysine-PEG28-folate) was coupled with succinoyl 
azadibenzocyclooctyne-N-hydroxysuccinimidyl ester (DBCO-NHS ester) by 
amidation, and the cysteine thiol group of the endosomolytic INF7 peptide was 
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conjugated with the maleimide group of DBCO-PEG4-Mal. Both DBCO coupled 
functional units were used to react with azidomethyl-methylmaleic anhydride 
(AzMMMan) modified RNase A protein by strain-promoted azide alkyne 
cycloaddition.  
In the presented delivery strategy, the AzMMMan linker90 serves two different 
purposes. First, it should connect the protein and the two functional units, 
targeting ligand and endosomolytic peptide, by efficient click chemistry to form 
a soluble  single-protein conjugate with cytotoxin-like properties (Figure 4.3-1a); 
second, after successful folate receptor-mediated cellular internalization, a 
traceless cleavage of the amide bonds between the AzMMMan-linkers and protein 
should take place in the acidic endosomal environment, releasing the original 
RNase A protein from without functional impairment91. Facilitated by a pH-
triggered endosomal escape activity of released INF7, cytosolic RNA degradation 
by RNase A is supposed to result in tumor cell killing (Figure 4.3-1b).  
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Figure 4.3-1. a) Synthesis of RNase A conjugates by extensive modification with acidic 
traceless linker AzMMMan (‘Az’), followed by copper free click chemistry coupling with the 
targeting ligand folate and the endosomal disruptive peptide INF7. b) Intracellular delivery of 
conjugates and traceless release of RNase after endocytosis. The RNase A structure adapted 
from PDB-101. (D. Goodsell, doi:10.2210/rcsb_pdb/mom_2008_9). 
4.3.2 Syntheses of RNase A conjugates 
The amino groups of RNase A were reacted with an excessive (8-fold molar) 
amount of the bifunctional AzMMMan linker, followed by removal of free 
AzMMMan, as reported in our former work.97 To quantify the numbers of RNase 
A amines which reacted with AzMMMan linker, residual free primary amines 
were determined by a biochemical TNBS assay. According to this assay, at least 
9 out of the 11 primary amines of RNase A (10 lysines plus one terminal amino 
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group)89 were modified with AzMMMan ( Figure 4.3-2).  
 
Number of attached AzMMMAn:  11-0,0574/0,0323*11=9,04 
Figure 4.3-2. TNBS assay for determination of the number of coupled AzMMMAn linkers. 
 
Next, to study the efficiency of copper free click chemistry, AzMMMan-modified 
RNase A was reacted with 11 eq of folate-PEG28-lysine-DBCO to generate folate-
PEG RNase A conjugate 1. HPLC was applied to monitor the reaction progress at 
different time points, by observing the decrease of the folate-PEG28-lysine-DBCO 
peak (Figure 4.3-3). After 40 min reaction time, 46% of folate-PEG28-lysine-
DBCO had coupled with RNase-AzMMMan; after 4 hours, almost 98% folate-
PEG28-lysine-DBCO had reacted with RNase A, indicating a high efficiency of 
RNase A modification with AzMMMan followed by click coupling with DBCO 
(Figure 4.3-3).  
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Figure 4.3-3. Reverse Phase HPLC to monitor the reaction process of folate-PEG28-lysine-
DBCO with RNase A-AzMMMAn to yield conjugate 1 (Waters Xbridge C18 column 5 μm, 4.6 
x 150 mm; Hitachi Chromaster 5160 pump module, 5260 auto sampler, 5310 column oven, 
5430 diode array detector, detect wavelength 280 nm, 0.1M TEAA buffer / acetonitrile).  a) 
HPLC of folate-PEG28-lysine-DBCO; b) HPLC of folate-PEG28-lysine-DBCO (11 equivalents) 
reacted with RNase A-AzMMMAn (one equivalent) for 40 min; c) HPLC of folate-PEG28-
lysine-DBCO reacted with RNase A-AzMMMAn for 4 hours. Under the latter conditions, 
folate-PEG28-lysine-DBCO without AzMMMan remains unchanged (not shown).  
Based on this successful coupling, a series of further RNase A conjugates was 
synthesized as displayed in Table 2. 
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Table 2. Synthesized RNase A conjugates. 
RNase A 
conjugate 
Molar equivalents of 
FolA-PEG28 INF7-Mal-PEG4 
1 11 - 
2 3 - 
FITC-folate-1 1 - 
FITC-folate-3 3 - 
3 3 2 
4 3 4 
5 3 6 
6 3 8 
7 - 8 
 
4.3.3 Receptor targeting of folate-PEG RNase A conjugates 
For cell binding and uptake studies, RNase A was first labeled with FITC and 
subsequently modified with AzMMMan linker as described above. Afterwards, 
two different RNase A conjugates (FITC-folate-1 or FITC-folate-3) were 
generated by copper free click reaction with 1 or 3 equiv of folate-PEG28-lysine-
DBCO, respectively (Table 2). Flow cytometry was used to evaluate the impact 
of folate-PEG conjugation on the cellular association (Figure 4.3-4a) and uptake 
of RNase A (Figure 4.3-5). Folic acid receptor positive KB cells were incubated 
with the two different RNase A conjugates (2 μM) and FITC-RNase A-
AzMMMan (2 μM). In a control experiment, cells were pre-incubated with free 
folic acid (400 µM) to competitively block receptor interaction.  
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Figure 4.3-4. a) Cellular association of FITC-folate-1 conjugates. b) Cellular association of 
FITC-folate-3 conjugates. Red, blank control without FITC-RNase A conjugates; blue, 2 μM 
FITC-RNase A-AzMMMan was added; brown, 400 μM free folate block for 30 min on ice 
before FITC-RNase A-folate conjugates were added; green, 2 μM conjugates. Incubation for 
45 min on ice.  c) Microscopy images of cells in fresh media (pH 7.4) (Top: Bright-field images 
of the treated cells; Bottom: FITC fluorescence of the treated cells) treated with RNase A 
conjugate FITC-folate-3 at different conditions for 2 h followed by 2 h incubation in fresh 
medium at 37 °C.  Left, KB cell incubated with 2 μM FITC-RNase A-AzMMMan; center, 400 
μM free folate block for 30 min on ice and then incubated with 2 μM RNase A conjugate FITC-
folate-3; right,  KB cell incubated with 2 μM RNase A conjugate FITC-folate-3.  A 63x 
magnification DIC oil immersion objective was used for image acquisition. Scale bar = 20 
µm.Experiments were carried out by Peng Zhang (PhD study, Department of Pharmacy, LMU).  
As expected, FITC-RNase A-AzMMMan without conjugated folate ligand could 
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neither bind to nor be internalized into KB cells, similar to folate-PEG RNase A 
conjugates after the receptor blockade by free folic acid. In contrast, cells 
incubated with folate conjugates (FITC-folate-1 or FITC-folate-3) showed 
distinct fluorescence indicating high cell binding ability. Cellular uptake studies 
(Figure 4.3-5) gave similar results as the association experiments, though the 
levels of cellular uptake were lower than cell association. KB cells pretreated with 
free folic acid did not show uptake of folate-PEG RNase A conjugates. As 
conjugation of RNase A-AzMMMan with one or three equivalent folate-PEG28 
did not result in any significant biological difference, all subsequent studies were 
made with a folate-PEG to RNase A ratio of 3:1. 
 Fluorescence microscopy of KB cells incubated with FITC-folate-3 conjugate 
for 2 hours at 37 oC followed by medium change and further 2 hours incubation 
(Figure 4.3-4b) confirmed intracellular uptake of RNase A conjugate FITC-
folate-3. Cells treated with FITC-RNase A-AzMMMAn control, or cells 
pretreated with free folic acid for receptor blockade before incubation with FITC-
folate-3 did not display intracellular delivery (Figure 4.3-4b). 
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Figure 4.3-5. Cellular internalization of FITC-RNase A-folate conjugates. Red, blank control 
without FITC-RNase A-folate conjugates; blue, 2 μM FITC-RNase A-AzMMMan was added; 
brown, free folate block for 30 min on ice before FITC-RNase A-folate conjugates were added; 
green, 2 μM conjugates. Incubation for 45 min at 37 °C. a) RNase A conjugate FITC-folate-1. 
b) RNase A conjugate FITC-folate-3. Experiments were carried out by Peng Zhang (PhD study, 
Department of Pharmacy, LMU).  
4.3.4 INF7 conjugates and traceless release of RNase A 
Next, four RNase A conjugates 3 to 6 containing both targeting folate-PEG28 and 
the endosomolytic INF7-PEG4 were synthesized, and two control conjugates, the 
corresponding folate-PEG28 RNase A conjugate 2, and INF7-PEG4 RNase A 
conjugate 7 (Table 2). SDS-PAGE of conjugates is displayed in Figure 4.3-6a. Gel 
migrations are different from unmodified RNase A but similar to AzMMMan-
modified RNase A (Figure 4.3-6d). The different conjugates 2 to 6 show the same 
gel migration, which probably is attributed to the same content of hydrophilic 
PEG28 chains; conjugate 7 lacking PEG28 chains but containing anionic, 
amphiphilic INF7 displays slightly more migration. For full enzymatic activity of 
RNase A, the removal of the chemical modifications is necessary. Our former 
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work demonstrated that RNase A modified with an irreversible SMCC linker or 
with the reversible AzMMMan linker but without acid treatment had insignificant 
activity. The RNase A activity of AzMMMan-modified protein however could be 
recovered by incubation in acidic buffer.97 To verify whether the AzMMMan-
based RNase A conjugation is also a reversible process for the current folate-PEG 
INF7 RNase A conjugates under the mild acidic conditions of endosomes, we 
incubated conjugates 3 to 6 in pH 6.0 buffer for 24 hours at 37 °C. The comparison 
of the SDS PAGE profile of conjugates (Figure 4.3-6a) with pH 6.0 treated 
conjugates (Figure 4.3-6b) clearly demonstrates the release of RNase A from 
conjugates. To further demonstrate that the release of the RNase A from the 
conjugate is a traceless process, MALDI-TOF MS of conjugate 6 after acidic 
incubation (pH 6.0, 24 hours at 37°C) was performed and the mass peak of free 
RNase A was detectable, in contrast to the conjugate without acidic treatment 
(Supporting Figure 4.3-6e). SDS-PAGE of RNase A incubated with PBS and 
acidic buffer (pH 6.0) did not show any alteration (Figure 4.3-6c), which indicates 
the stability of RNase A under the treatment conditions.   
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Figure 4.3-6. SDS-PAGE of (a) RNase A conjugates and (b) acidic cleavage of RNase A 
conjugates after incubation for 24 hours at 37 oC in acidic pH 6.0 buffer. M, marker protein 
ladder; R, RNase A control; 3 to 6, folate-PEG28 INF7-PEG4 RNase A conjugates; 2, folate-
PEG28 RNase conjugate; 7, INF7-PEG4 RNase A conjugate. (c) R-PBS, RNase A incubation for 
24 hours at 37 oC in PBS (pH 7.4); R-pH6, RNase A incubation for 24 hours at 37 oC in acidic 
pH 6.0 buffer. (d) SDS-PAGE of RNase A (middle) and RNase A-AzMMMan (right). 10 μg 
RNase A samples were loaded in each lane.  (e) MALDI-TOF MS of conjugate 6 after acidic 
cleavage. Above: Fresh RNase A (13756.75). Under these conditions, conjugate 6 did not show 
any measurable mass peak. Below: After acidic cleavage (conjugate 6 pre-incubated in pH=6.0 
buffer for 24 hours at 37 °C), RNase A was found (13756.78). 
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4.3.5 RNase A conjugates activity at various pH values 
The enzymatic activity of RNase A and its conjugate incubated under various pH 
values were monitored using an ethidium bromide (EtBr) fluorescence assay 
(Figure 4.3-7). The fluorescence intensity of solutions containing 0.5 ng EtBr and 
20 µg RNA in 1 mL of PBS (pH = 7.4) was first monitored during an equilibration 
time of 5 min. Then RNase A samples were added, and decrease of fluorescence 
intensity was monitored for another 5 min. The enzymatic activity was the same 
when RNase A was incubated in PBS (pH 7.4) or acidic buffer (pH 6.0) as 
compared to fresh RNase A, indicating the stability of RNase after incubation 
under different conditions. Fresh RNase A conjugates without incubation and 
RNase A conjugates incubated in PBS (pH 7.4) for 24 hours show the same low 
bioactivity. Apparently the release of free bioactive RNase from RNase A 
conjugates is negligible when treated at pH 7.4. In contrast, when RNase A 
conjugate was incubated in acidic buffer (pH 6.0), the EtBr fluorescence shows 
significant decrease, which implies that RNase A was released from the conjugate 
and regained its bioactivity.  
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Figure 4.3-7. Enzymatic activity of RNase A conjugates (3, 4, 5, 6) and RNase A measured by 
an ethidium bromide assay. First row, fresh RNase A conjugates and RNase A without pre-
incubation. Second row, RNase A conjugates and RNase A after pre-incubation in PBS at 37 °C 
for 24 hours. Third row, RNase A conjugates and RNase A after pre-incubation in acidic buffer 
(pH 6.0) at 37 °C for 24 hours. The first five minutes represent the incubation of RNA with 
EtBr; after five minutes, RNase A samples were added and the decay of RNA-based EtBr 
fluorescence was measured for five minutes.  
4.3.6 RNase A conjugates with pH-dependent lytic activity 
INF7 is a negatively charged amphiphilic peptide derived from the N-terminus of 
the influenza virus hemagglutinin HA 2 subunit; due to sequence variations with 
glutamic acids it has endosomal pH-specific lytic activity.109-110, 123 To evaluate the 
lytic activity of the INF7 containing RNase A conjugates, an erythrocyte leakage 
assay (Figure 4) was performed. Different concentrations (1 μM, 2 μM, 4 μM) of 
unmodified RNase A and its conjugates 2 to 6 were incubated with human 
erythrocytes at various pH conditions (pH 7.4, 6.5, and 5.5), and the degree of 
hemoglobin release was measured (Figure 4). No significant lytic activity was 
found for RNase A and folate conjugate 2. For INF7 containing RNase A 
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conjugates 3 to 6, concentration and pH-dependent lytic activities were found, 
which were highest at pH 5.5, consistent with the known pH-specific leakage 
profile of unmodified INF7.109-110, 123 Taking conjugate 3 at the lowest tested 1 µM 
concentration as an example, the percentage of release hemoglobin was 87% at 
pH 5.5 compared to 19% at pH 7.4 and 73% at pH 6.5. Conjugates 4 to 6 also 
showed a similar trend. Not surprisingly, conjugate 6 with highest degree of INF7 
conjugation also revealed the highest lytic activity amongst all conjugates. The 
same concentration of free INF7 and INF7-PEG as contained within conjugate 6 
performed a higher lytic ability in comparison with the conjugate (Figure 4.3-8). 
This might be explained by a higher steric hindrance within the conjugate, 
reducing the lytic ability of INF7. The AzMMMan-triggered endosomal acidic 
cleavage from the conjugate would result in favorably increased INF7 activity in 
the endosome.  
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Figure 4.3-8. Leakage activity of INF7 measured by erythrocytes leakage assay.  a),b),c) RNase 
A, RNase A-PEG-folate conjugate 2, and RNase A-PEG-folate-INF7 conjugates 3 to 6; were 
incubated at indicated concentrations with erythrocytes at indicated pH values. d),e),f) INF7 
and INF7-PEG was tested at various concentrations corresponding to the amounts of INF7 
using conjugate 6, 7. *: compared with pH 6.5; •: compared with pH 5.5. *p < 0.05, **p < 0.01, 
***p < 0.001, •p < 0.05, •••p < 0.001. Experiments d), e), f) were carried out by Peng Zhang 
(PhD study, Department of Pharmacy, LMU).  
4.3.7 Cytotoxicity of RNase A conjugates 
In the following, to assess the intracellular transduction and cytotoxicity of the 
RNase A conjugates, cell viability assays (MTT) were performed. The remaining 
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biological activity of KB tumor cells after treatment with various concentrations 
of RNase A conjugates was analyzed after 48 hours (Figure 4.3-9a). Cells treated 
with RNase A conjugate 7 (INF7-modified only) did not display any significant 
reduction in cell viability, similarly as free RNase A43 91.  Conjugate 7 is most 
likely not sufficiently internalized for successful transduction. Also conjugate 2 
(folate-modified only) and conjugate 3 (with the lowest degree of INF7 
incorporation) showed an only ~40% reduced metabolic cell viability at the 
highest dose. The slightly higher potency of these conjugates over 7 can be 
attributed to the efficient folate receptor mediated cellular uptake, however 
insufficient endosomal escape (no or insufficient INF7) apparently hampers the 
cytotoxic activity. RNase A conjugates 4 to 6 showed the desired high cytotoxicity 
(Figure 4.3-9a) correlating with the degree of INF7-modification and RNase A 
conjugate concentration. For each conjugate, KB cells treated with 8 μM exhibited 
the lowest cell viabilities, 7% vs. 2% vs. 1% for conjugates 4 to 6, respectively. 
Based on the intracellular delivery analyzed for the RNase A-FITC-folate 
conjugates (Figure 4.3-4a) and the leakage assays (Figure 4.3-8), it is hypothesize 
that the RNase A conjugates with the same degree of PEG-folate modification 
undergo a similar intracellular uptake. However, after endocytosis, the endosome-
disruptive ability of INF7 in a pH- and concentration-dependent manner (compare 
Figure 4.3-8), would well explain why conjugate 6 with highest INF7 content and 
lytic activity also exhibits the strongest tumor cell killing effect.  
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Figure 4.3-9. Cytotoxic potency of RNase A conjugates and free INF7. a) Viability of KB cells 
(MTT) after treatment with RNase A-PEG-folate conjugate 2, RNase A-PEG-folate-INF7 
conjugates 3 to 6, or RNase A-PEG-INF7 conjugate 7 at different concentrations for 48 hours.  
b) A noncovalent mixture of conjugate 2 with 8 equiv of INF7 was prepared and tested in KB 
cell killing with or without dialysis against PBS buffer (for removal of INF7). c) KB cells 
treated with indicated concentrations of free INF7. Experiments were carried out by Peng Zhang 
(PhD study, Department of Pharmacy, LMU).  
To evaluate whether free INF7 may enhance the cytotoxic activity of the folate-
RNase A conjugate 2, the conjugate was mixed with 8 equivalents of INF7. As 
shown in Figure 4.3-9b, this resulted in significantly enhanced cytotoxicity (16% 
metabolic activity as compared with 60% for 2) at the 8 µM high RNase A 
concentration, however by far not as high as for the corresponding covalent INF7 
conjugate 6. Free INF 7 is a small amphipathic peptide which has been found to 
bind to the surface of lipid membranes at pH 7.4 without lytic insertion, and thus 
may be simultaneously internalized with the protein conjugate and promote 
endosomal escape, though less effectively as via AzMMMan linkage.  
c) 
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Furthermore, dialyzing the 2/INF7 mixture according due the standard conjugate 
purification process, which should remove non-bound INF7, abolished most of 
the cytotoxic activity (Figure 4.3-9b). Meanwhile, INF7 and RNase A alone did 
not trigger any significant cytotoxicity (Figure 4.3-9c, a).
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5 DISCUSSION 
 
5.1 Histidine rich-cationic modified RNase A conjugates for 
enhanced cellular delivery and tumor cell killing 
Intracellularly-acting therapeutic proteins are considered promising alternatives 
for the treatment of various diseases. Major limitations of their application are 
low efficiency of intracellular delivery and possible reduction of protein activity 
during derivatization. Herein, a pH reversible linker AzMMMan was first applied 
to modify with nlsEGFP, a moderate size protein which could be revealed as a 
standard example for delivery of other kinds of protein, and RNase A, a 
cytotoxicity protein to degrade the RNA in the cytosol then result in the death of 
the RNase A intracellular cells. Successful AzMMMan modification of EGFP 
could be confirmed by UV spectroscopy, since AzMMMan and EGFP-
AzMMMan have an intensive absorbance around 240 nm comparing to non-
modified EGFP (Figure 4.1-4).  The sequence-defined oligoamino amides 689 and 
386 were synthesized by solid phase synthesis, and the three contained cysteines 
were modified with DBCO-PEG4-Maleimide. The DBCO coupled oligomer were 
then used to modify with AzMMMan linker-proteins by strain promoted azide 
alkyne cycloaddition.  
Different ratios of oligomers (386, 689) to protein conjugates were synthesized, 
SDS-PAGE of the conjugates shows a gradual shift of the protein band toward 
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lower migration distance with increasing 689/386 to protein ratio (Figure 4.1-5), 
demonstrated the high reactive efficiency of the click chemistry between –N3 
from modified protein and DBCO from oligomer.  Meanwhile, fluorescence 
correlation spectroscopy (FCS) also indicates the different coupled ratios by 
detecting hydrodynamic radii of fluorescent molecules, higher ratios oligomer 
modified EGFP shows larger hydrodynamic radii (Figure 4.1-6).  
Then flow cytometry was used to test the intracellular efficiency of EGFP 
conjugates modified by a series ratios of oligomer 689 (Figure 4.1.7). Uptake of 
content EGFP conjugate is increasing with the modified degree of  oligomer , 
which could explained by higher intracellular efficiency because of higher 
protonatable ability with more oligomer conjugation.  And a comparison study 
between the two similar cationic oligomers 386 and 689 has been carried out. 
Oligomer 386 is also a three-arm cationic STP-based oligomer, having been 
successfully used for siRNA, DNA, and protein delivery before, but 689 
additionally contains histidines after each STP unit to enhance endosomal 
buffering. The flow cytometry results show 386 and 689 oligomer modified EGFP 
being internalized into cells to comparable extent (Figure 4.1.7). In the 
extracellular environment, the pH is about 7.4, and the additional histidines in 689 
are not protonated. Therefore, these two oligomers mediate similar uptake of 
modified EGFP.  The visible of various ratios of oligomer modified nls EGFP was 
detected by florescence microscopy, all degrees of oligomer modified nlsEGFP 
reveals successfully intracellular (Figure 4.1-10), though at the ratio of 16 
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oligomer to EGFP has very high intracellular efficiency,  but only optimization 
ratios of oligomer to nlsEGFP shows some extend of nuclei delivery (Figure 4.1-
9).  This highlights the importance of modification degree when designing a 
covalent carrier for –NH2 rich protein.  
Then RNase A conjugates treated at different pH values and then performed by 
SDS-PAGE demonstrated the high stable ability of the conjugate when incubated 
at  extracellular pH 7.4, but traceless cleavage when incubated in acidic buffer pH 
5 (Figure 4.1-11). This is very important for designing a protein vector, first, to 
form a stable formation between the protein and delivery units in extracellular 
environment has always been a main aim for protein therapeutics, and many 
electrostatic method is not strong enough for this application. Second, when the 
protein formation arrives in the target place, the formation should release protein 
content without any dysfunction of the protein, thus requires the stable formation 
of the first step is a reversible process, which means could be traceless release of 
functional protein. Ethidium bromide assay was performed to test the enzymatic 
activity of RNase A and its conjugates also verify the same result as SDS-PAGE 
gel (Figure 4.1-12). The RNase A conjugates connected by AzMMMan linker 
incubated in alkaline buffer shows very low activity, due to the unsuccessful 
release of RNase A in high pH values, also similar trend when RNase A modified 
with an irreversible linker SMCC (Figure 4.1-13). Meanwhile, when RNase A 
conjugates bridged by AzMMMan linker incubated in acidic buffer, RNase A 
shows regain its enzymatic activity because of the covalent bond traceless 
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breakage between RNase A and AzMMMan. 
To verify that the covalently modified therapeutic protein can be successfully 
delivered into the cytoplasm and then perform its enzymatic lytic activity for 
traceless release of RNase A, cell viability assays (MTT) were performed with the 
two series of oligomer (689 and 386) modified RNase A to investigate the 
biological activity and effect on tumor cell viability after 48 h treatment (Figure 
4.1-14, Figure 4.1-15).  For the same series of oligomer (689 or 386) modified 
RNase A conjugate at the same concentration, the toxicity increased with the 
degree of conjugation (386/689: RNase A=0.75, 1.5, 3, 6), which means higher 
degree oligomer performed higher intracellular ability, and thus result in higher 
cytotoxicity. From the perspective of oligomer structure, 689 modified RNase A 
conjugates exhibit higher activity than 386 modified RNase A conjugates, this 
could be explained by 689 equipping with one more histidine after each STP than 
386, histidine could be protonatable in endosomal environment, enhancing 
endosomal escape efficiency and resulting in higher cytotoxicity.    The 
cytotoxicity of RNase A conjugates modified by oligomer 689 is increasing with 
the treated concentrations, which could be explained by a dose independence of 
the therapeutics RNase A. 
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5.2 Traceless reversible conjugation of proteins with receptor 
targeting and endosomal escape domains 
Multifunctional single-protein conjugates as a novel cytotoxin-like intracellular 
transduction platform were investigated, utilizing receptor-mediated 
internalization, pH-dependent lytic activity and intracellular release of functional 
proteins into the cytosol. The chemical strategy to assemble the multifunctional 
protein conjugates is based on the pH-labile bifunctional AzMMMan linker, 
which provides a connectivity between the protein cargo and functional units with 
pH-dependent cleavage. 
EGFP performs as a visible protein modified with DBCO-folate and DBCO-INF7, 
DBCO-folate exhibits targeting function units to the receptor of KB cells and 
DBCO-INF7 works as endosomal escape to make EGFP release into the 
cytoplasm, binding and uptake of EGFP conjugates show correlation with degree 
of coupled folate, and show successful intracellular delivery (Figure 4.2-9), but 
no obvious nuclear delivery was observed. Possible reason could be the nuclear 
localization signal (NLS) was also modified and the traceless efficiency was not 
enough, because EGFP contains 27 amino groups, it requires time and acidic 
environment to break these modified –NH2 groups. 
 RNase A was used as the bioactive component which was intended to degrade 
cytosolic RNA and induce cell death after intracellular delivery.104 In contrast to 
nanoparticle-based cationic polymer based delivery systems which can cover 
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several delivery steps at once, however at the expense of generally less defined 
nanoparticulate charged complexes, here - similar to natural protein toxins 
comprising separate subunits for specific purposes - an artificial small protein 
conjugate containing different defined components was assembled. RNase A was 
covalently modified with a PEG-folate targeting unit and an endosomal disruptive 
peptide INF7 unit at different ratios based on the pH-labile AzMMMan linker and 
copper free click chemistry. The efficiencies of the separate modification steps, 
amidation and subsequent click reaction, were evaluated by the quantification of 
free amines after AzMMMan modification by TNBS assay (Figure 4.3-2) and 
monitoring the depletion of free folate-PEG28-lysine-DBCO during click reaction 
by RP-HPLC (Figure 4.3-3). According to the results, both steps showed high 
efficiency with at least 9 out of 11 AzMMMan modified primary amines and 
almost 98 % conversion of a stoichiometric amount of folate-PEG28-lysine-DBCO 
after 4 h. The biological effect of each functional unit of the RNase A conjugates 
was assessed in separate experimental settings. Flow cytometry and fluorescence 
microscopy with FITC-labeled RNase A variants demonstrated that binding and 
uptake of RNase A-folate conjugates depended on PEG-folate attachment and pre-
incubation with free folate could block the cellular interactions which both 
confirmed the receptor specificity of the conjugates (Figure 4.3-4, Figure 4.3-5). 
The biological effect of additional INF7 functionalization was assessed in an 
erythrocyte leakage assay (Figure 4.3-8) as model for pH-dependent membrane 
disturbing and potential endosomolytic activity after cellular uptake. The 
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concentration and pH-dependent lytic activities of INF7 containing RNase A 
conjugates confirmed the potency of the endosomolytic component for the 
intended purpose. INF7 within the conjugate showed a significant but lower lytic 
activity as compared to the unmodified INF7, presumably due to a  higher steric 
hindrance when protein-bound. Consistent with the requirement to overcome both 
critical limitations, cellular uptake and endosomal escape, for RNase A triggered 
cell death, only conjugates modified with both PEG-folate ligand and INF7 
peptide showed killing of KB tumor cells, with a clear correlation of 
endosomolytic INF7 content and cytotoxic antitumoral activity. The results of the 
separate evaluations confirm the functionality and requirement of each of the units 
which are assembled to the multifunctional RNase A conjugate complexes. 
Importantly, the traceless AzMMMan linker strategy which provides programmed 
connectivity for the functional units, also ensures recovery of the enzymatic 
activity after acidic exposition, which could not be guaranteed in case of 
irreversible modification techniques.97 The use of pH-sensitive INF7 as the 
endosomolytic entity is an additional dynamic element, which changes its 
properties in a changing environment.  These kinds of bioresponsive dynamics 
are required to fulfill the specific tasks within the intracellular delivery pathway 
of biomacromolecules efficiently and therefore are also inherent part of several 
natural delivery complexes, e.g. protein toxins or viruses. Analog to the highly 
specific natural counterparts, in the design of these artificial immunotoxins, the 
sequential function and activation of subunits (folate for receptor-specific binding 
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extracellularly, activation of INF7 in endosomes, reactivation of RNase A after 
acidic exposition intracellularly) is intended to balance the opposing factors of 
high cytotoxic activity and safety. Taking all together, this work suggests that a 
synthetic traceless reversible conjugation of therapeutic cargo proteins such as 
RNase A with cytotoxin-like delivery domains for receptor targeting and 
endosomal escape might be an effective delivery strategy for intracellularly acting 
antitumoral proteins. For further translation toward in vivo administration in 
animal tumor models or even clinics, a series of aspects have to be considered 
with great care. Firstly, the residual lytic activity of the pH -sensitive peptide INF7 
observed in the standard erythrocyte leakage assay requires attention. The assays 
however were performed under artificial serum-free conditions, which are not 
predictable for the in vivo conditions in blood. Secondly, the pharmacokinetic 
properties with regard to tumor targeting will strongly depend on the size and 
surface of the formulation115 124 125. Small soluble protein conjugates probably 
strongly differ from commonly used nanoparticle formulations, with regard to 
accessibility of tumors from the systemic circulation and better intratumoral 
distribution on the one hand, and the increased kidney clearance and reduced 
circulation-time of the small soluble protein conjugates on the other hand.  Size 
and density of the PEG shielding domain and proper targeting ligands will be 
important factors for optimization. 
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6 SUMMARY 
The specific transport of bioactive proteins into designated target cells is an 
interesting and challenging perspective for the generation of innovative 
biopharmaceuticals. In this thesis two strategies were applied for intratumoral 
delivery of proteins followed by traceless intracellular release in bioactive form.  
In the first part, covalent protein conjugates based on pH sensitive components 
were developed as intracellular delivery platform. Cationic three-arm oligoamino 
amide oligomer 386 or its histidinylated analog 689 were conjugated with proteins 
(EGFP or RNase A) at different molar ratios using the pH-labile AzMMMan 
linker and copper-free click chemistry. Fluorescence correlation spectroscopy 
measurements of 689-EGFP conjugates revealed that the formation of crosslinked 
protein clusters strongly depends on the conjugation degree. The conjugation 
degree had also effects both on the amount of protein conjugate taken up by cells 
and the extent of nuclear delivery after endosomal escape. All four kinds of 
cationic oligomer modified EGFP (689: EGFP = 2, 4, 8, 16) have efficient 
internalization capability, but only EGFP conjugates (689: EGFP = 4, 8) showed 
nuclear delivery. Furthermore, therapeutic protein RNase A conjugates were 
investigated as cancer cell killing agents. The cationic oligomer 689 modified 
RNase A showed pH dependent bioactive release in in vitro experiments and high 
ability to kill cancer cells. Consistent with the known higher endosomal escape 
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efficacy due to incorporated histidine residues, conjugates of 689 demonstrated 
higher delivery efficacy than 386 conjugates. Taking together, this study suggests 
that fine-tuning of pH reversible conjugation of therapeutic proteins with potent 
intracellular transfection oligomers opens a new window for future medical 
applications. 
The second and third part reports multifunctional single-protein conjugates as a 
novel cytotoxin-like intracellular transduction platform, utilizing receptor-
mediated internalization, pH-dependent lytic activity and intracellular release of 
functional proteins into the cytosol. RNase A was covalently modified with a 
PEG-folate targeting unit and an endosomal disruptive peptide INF7 unit at 
different ratios based on the pH-labile AzMMMan linker and copper free click 
chemistry. TNBS assays and HPLC showed RNase A successfully coupling with 
AzMMMan and then modification with DBCO-folate/INF7, flow cytometry 
demonstrated the intracellular uptake of RNase A-folate conjugates. Only RNase 
A conjugates modified with both PEG-folate ligand and INF7 peptide showed 
effective killing of KB tumor cells (by MTT assay), with a clear correlation of 
degree of INF7 incorporation and cytotoxic antitumoral activity. Taking all 
together, this work suggests that a synthetic traceless reversible conjugation of a 
therapeutic cargo protein (RNase A) with cytotoxin-like delivery domains for 
receptor targeting and endosomal escape can be an effective delivery platform for 
protein therapeutics.
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7 ABBREVIATIONS 
μM: Micromolar 
μmol: Micromole 
ACN: Acetonitrile 
AzMMMan: 3-(Azidomethyl)-4-methyl-2, 5-furandione 
BCA: Bicinchoninic acid assay 
BrMMMan: 3-(bromomethyl)-4-methyl-2, 5-furandione 
BOC: Tert-butoxycarbonyl 
Boc2O: Di-tert-butyl dicarbonate 
BSA: Bovine serum albumin 
cm: centimeter 
CPP: Cell-penetrating peptide 
Da: Dalton 
DBU: 1,8-diazabicyc [5.4.0] undec-7-ene 
DBCO: Azadibenzylcyclooctyne  
DCM: Dichloromethane 
DCVC: Dry column vacuum chromatography 
DMF: Dimethylformamide  
DMSO: Dimethyl sulfoxide 
DNA: Deoxyribonucleic acid  
ABBREVIATIONS 
 
108 
 
DIPEA: N,N-diisopropylethylamine 
DODT: 3,6-dioxa-1,8-octanedithiol   
EDTA: Ethylenediamine tetraacetic acid 
Et2O: Diethyl ether 
FBS: Fetal bovine serum  
EGFP: Enhanced Green fluorescent protein 
FDA: Food and Drug Administration 
FITC: Fluorescein isothiocyanate 
Fmoc: Fluorenylmethyloxycarbonyl 
FR: Folic acid receptor 
g: Gram 
Hepps, 4-(2-hydroxyethyl)-1-piperazinepropanesulfonic acid 
HOBt: 1-Hydroxy-benzotriazole  
HPLC, high performance liquid chromatography  
INF7: Influenza hemagglutinin HA-2 terminal peptide derivative 7 
IPTG: Isopropyl-β-D-thiogalactopyran oside 
IU: International Units 
mg: Milligramm 
mL: Milliliter 
mM: Millimolar 
mmol: Millimole 
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Mal: Maleimide 
MeOH: Methanol 
MTT: 1-(4,5-Dimethylthiazol-2-yl)-3,5-diphenylformazan 
NHS: N-Hydroxysuccinimide 
nm: nanometer 
NLS: Nuclear localization signal 
nlsEGFP: Nuclear localization signal tagged EGFP 
kDa: kilo Dalton 
PAGE: Poly Acrylamide Gel Electrophoresis 
PBS: Phosphate buffered saline 
PD-1: Programmed cell death protein 1 
PEG: Poly(ethylene glycol)  
pH: Potentia Hydrogenii 
PTD: Protein-transduction domain 
RNA: Ribonucleic acid 
RNase A: Ribonuclease A 
SA: Streptavidin  
SDS: Sodium dodecyl sulfate 
SEC: Size exclusion chromatography 
SMCC: N-Succinimidyl 4-(maleimidomethyl)cyclohexanecarboxylate 
SPAAC: Strain-promoted alkyne-azide cycloaddition 
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Stp: Succinoyl-tetraethylenpentamine 
SWNT: Single-walled carbon nanotube TCEP: Tris(2-carboxyethyl) phosphine 
TEPA: Tetraethylenepentamine  
TFA: Trifluoroacetic acid  
THF: Tetrahydrofuran 
TIS: Triisopropylsilane 
TLC: Thin layer chromatography 
TNBS: 2,4,6-Trinitrobenzenesulfonic  
Tris: Tris(hydroxymethyl)aminomethane 
TSE: Transmissible spongiform encephalopathies 
UV: Ultraviolett 
Vis: Visible 
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